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Abstract 
Atherosclerosis, a chronic inflammatory disorder of the vasculature, is the underlying 
cause of heart attacks and stroke and responsible for most deaths in western society. A 
range of cytokines regulates the initiation, progression and clinical complications of 
atherosclerosis and affects all the cell types present in a lesion. Macrophages play an 
important role in all stages of the disease from the uptake of modified lipoproteins to 
amplification of the inflammatory response to plaque rupture.  
Because of the key roles of cytokines in atherosclerosis, it is important that their effects 
on macrophage properties and gene expression are fully understood. Although the 
action of classical cytokines, such as interferon-γ (IFN-γ), on macrophages and 
atherosclerosis is well understood, this is not the case with those that have been more 
recently identified such as interleukin (IL)-15, -20, -22 and -37. The aim of this study 
was therefore to investigate the effect of these cytokines using human THP-1 
macrophages and mouse RAW264.7 macrophages as model systems. The action of 
IFN-γ was used as a positive control.  
Real-time quantitative polymerase chain reaction showed that IFN-γ induced the mRNA 
expression of two markers of inflammation, monocyte chemoattractant protein-1 (MCP-
1) and intercellular adhesion molecule-1 (ICAM-1), in THP-1 macrophages. From the 
other cytokines analysed, IL-20, IL-22 and IL-37 had no effect on the expression of 
these genes. In contrast, IL-15 inhibited the mRNA expression of both MCP-1 and 
ICAM-1. Western blot analysis indicated that the changes in ICAM-1 mRNA 
expression by IFN-γ and IL-15 were accompanied by corresponding changes at the level 
of the protein. Initial experiments on the effect of IFN-γ or IL-15 on the uptake of 
modified low-density lipoprotein by THP-1 macrophages were also carried out though 
firm conclusions could not be made and further optimisation will be required. 
The effect of IL-15 on MCP-1 mRNA expression in human THP-1 macrophages 
contrasted with a previous study that showed induced expression in mouse RAW264.7 
macrophages. Experiments in these cells indeed showed that IL-15 induced the mRNA 
expression of MCP-1, and also ICAM-1. The studies provide new insight into the action 
of recently identified cytokines on macrophage gene expression and suggest the 
potential existence of species-specific effects of IL-15 that needs to be further 
investigated. 
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1.1 An Overview  
 
Atherosclerosis, which comes from the Greek word “athero” (meaning gruel or paste) 
and “sclerosis” (hardness) (The American Heart Association, 2010), is the principle 
cause of cardiovascular disease (CVD) and responsible for approximately 40% of all 
deaths in the western world. It is a chronic inflammatory disease that is characterised by 
the accumulation of lipids and fibrous elements in medium and large arteries (Lusis et 
al. 2004; Moore and Tabas, 2011). Coronary heart disease (CHD) and stroke are the 
major CVD (George and Lyon, 2010). Based on the data from the British Heart 
Foundation, the number of premature deaths caused by CVD in 2008 was more than 
50,000 in the UK (28% men and 20% women) (Scarborough et al. 2010). The incidence 
of CVD in developing countries is also increasing as they acquire westernised lifestyles. 
Moreover, because of the global increase in diabetes and obesity, it is anticipated that 
CVD will be the major killer worldwide in the near future (Libby, 2002).   
Atherosclerosis starts early in childhood and progresses during the lifetime of an 
individual due to several risk factors (Berenson, 2002). The pathogenesis of 
atherosclerosis involves several cell types, such as endothelial cells (ECs), smooth 
muscle cells (SMCs), macrophages and T lymphocytes (Montecucco et al. 2007).  
 
1.2 Risk Factors 
 
There are numerous environmental and genetic risk factors that influence the 
development and progression of atherosclerosis (Lusis, 2000). Major risk factors 
include obesity, hypertension, diabetes, high levels of cholesterol (Lusis et al. 2004), 
age, smoking, physical inactivity and stress (Harvey and Ramji, 2005). Many of these 
risk factors are not reversible but some can be modified (George and Johnson, 2010). 
Table 1.2.1 lists some genetic and environmental risk factors in atherosclerosis. 
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Table 1.2.1 Genetic and environmental risk factors in atherosclerosis  
 
Environmental Risk Factors  
 
• Smoking 
 
• High fat diet 
 
• Lack of exercise 
 
• Low anti-oxidant intake 
 
• Infection  
 
• Obesity 
 
• Type II diabetes 
 
• Elevated blood pressure 
 
Genetic Risk Factors 
 
• Elevated plasma C-reactive protein 
 
• Gender 
 
• Age 
 
Adapted from Glass and Witztum, 2001; and Lusis et al. 2004 
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1.2.1 Age 
It is known that age is one of the most significant unmodified risk factor for CVD 
(Stocker and Keaney, 2004). According to a study in the United States, the percentage 
risk of developing CVD is sevenfold more in males aged 60-64 years than those aged 
30-34-years (Wilson et al. 1998).  
 
1.2.2 Gender 
Many studies have shown that, in contrast with aged-matched females, males are more 
at risk from CVD (Barrett-Connor and Bush, 1991). It is generally believed that 
oestrogen provides women with protection against the development of CVD, but not 
after menopause. However, this is difficult to prove since treatment with estrogens in 
women after menopause does not reduce CVD (Kleemann et al. 2008). It has also been 
suggested that some of this protection is related to the fact that women compared with 
age matched men have higher levels of the protective high density lipoproteins (HDL) 
(Stocker and Keaney, 2004). HDL is a type of lipoprotein that is usually known as good 
cholesterol since it works by removing unwanted cholesterol from the peripheral tissues 
to the liver for excretion via the bile system (McLaren et al. 2011). 
 
1.2.3 Smoking 
 Numerous studies have identified a relationship between smoking and risk of CHD 
(Buechley et al. 1958). A study by a group of British doctors found that smokers over 
50 were at a 60% higher risk of developing CHD (80% higher risk for heavy smokers) 
than non-smokers aged 50 and over. Smoking appears to decrease levels of HDL, 
increase the concentration of atherogenic low density lipoprotein (LDL), cause damage 
to the wall of artery within the endothelial lining and impair the function of the 
endothelium (Altman, 2003). 
 
1.2.4 Obesity and body mass index 
The risk of CHD increases with obesity and high BMI. Although obesity is an 
independent risk factor in CHD, it often predisposes the individual to other risk factors 
such as diabetes, increased blood cholesterol levels and high blood pressure (George 
and Johnson, 2010). The increase in obesity is demonstrated by a study in England  
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which reported that the percentage of obese men aged 16 or over rose from 14% to 25% 
between 1994 and 2008 respectively, while the percentage of obese women increased 
from 19% in 1994 to 28% in 2008 (Scarborough et al. 2010). A major current concern is 
the increase in obesity in developing countries (Stocker and Keaney, 2004). 
 
1.2.5 Diabetes 
The risk of CHD increases with diabetes as many studies have shown that the risk is 2-
4-fold higher in men with type 2 diabetes (non-insulin dependent diabetes) and about 3-
5-fold higher in females (George and Johnson, 2010). Hyperglycaemia is caused when 
the level or function of insulin is insufficient (Libby et al. 2002; Lusis et al. 2004). 
Diabetes is also known to influence the effect of other risk factors for CHD, such as 
obesity, elevated blood pressure and high levels of cholesterol (Yusuf et al. 2004). 
 
1.2.6 High blood pressure 
High blood pressure is known to be one of the most serious health problems that 
predisposes an individual to atherosclerosis (Stocker and Keaney, 2004). 
INTERHEART studies have shown that the percentage of heart attacks in Western 
Europe among patients who have a history of high blood pressure is 22% (Yusuf et al. 
2004). It is possible to lower blood pressure by drug treatment, weight loss, increasing 
physical activities and reducing the intake of alcohol (Scarborough et al. 2010). 
 
1.2.7 High cholesterol levels 
The risk of CHD is also directly proportional to high levels of plasma LDL cholesterol 
(Gotto, 2011). High levels of LDL is one of the major risk factors that can lead to the 
progression of atherosclerosis even in the absence of other risk factors (Glass and 
Witztum, 2001). Many epidemiological studies and clinical trials using cholesterol-
lowering drugs, statins, have reported a reduction in CVD with a decrease in plasma 
LDL cholesterol levels (Sacks et al. 1996; Liao and Laufs, 2005). According to the 
WHO, high total blood cholesterol is responsible for over 60% of CHD and about 40% 
of ischemic stroke in developed countries (George and Johnson, 2010). The 
inflammatory response that is triggered in atherosclerosis due to damage or activation of  
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the endothelium is mainly a result of high levels of LDL (Singh and Ramji, 2006). It is 
possible to reduce blood cholesterol levels through a change in diet, physical activity 
and drugs such as statins (Scarborough et al. 2010). 
 
1.2.8 Genetic risk factors 
Many genetic risk factors for cardiovascular disease have been identified. For example, 
it is known that mutation in genes such as lipoprotein lipase (LPL), the LDL receptor 
(LDLR), apolipoprotein E (ApoE), and the ATP-binding cassette transporter (ABC) A1 
significantly increases risk for cardiovascular disease (Puddu et al. 2005). 
 
1.3 Lipoproteins and atherosclerosis 
 
Insoluble lipids are transported in the blood in lipoproteins particles. Lipoproteins 
consist of a core region, with triacylglycerols and cholesterol esters, surrounded by a 
polar region consisting of phospholipids and apolipoproteins (Beisiegel, 2008). As 
mentioned above, high levels of plasma cholesterol appears to be unique because of its 
ability to drive the progression of atherosclerosis in humans and experimental animal 
models even in the absence of the various other environmental and genetic risk factors 
(Glass and Witztum, 2001). 
  
Cholesterol is a sterol that is essential for membrane fluidity and most of it is formed in 
the body by de novo synthesis. Cholesterol can also be consumed in the diet and needs 
to be transported to different parts of the body where it is needed. Several lipoprotein 
particles carry serum cholesterol and triacylglycerols. Overall, five major types of 
lipoproteins can be distinguished, including chylomicrones, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), LDL and HDL (Gotto et 
al. 1986; McLaren et al. 2011). The different types of lipoproteins are presented in 
Figure 1.3.1 where their roles in the transport of cholesterol and triacylglycerols are also 
described. 
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Figure 1.3.1 Lipoprotein particles and their roles in cholesterol transport. Adapted 
from McLaren et al. 2011 
 
1.4 History of Atherosclerosis 
 
Atherosclerosis is now well accepted as a chronic inflammatory disease of the large and 
medium arteries (Hansson, 2005; Tedgui and Mallat, 2006). In 1755, the term atheroma 
(from Greek meaning “lump of gruel”) was first used by Albrecht von Haller to describe 
the intimal degenerative process that he noticed in the arteries (Tedgui and Mallat, 
2006). Since that time there have been several opinions and much discussion about the 
major cause of atherosclerosis as a result of medical and scientific research into the 
disease. In the early 1900, it was generally believed that atherosclerosis was due to the 
aging process (McLaren et al. 2011). Thereafter, Rudolf Virchow (1821–1902), one of 
the major contributors to the thrombosis view, suggested that atheroma was likely to be 
a chronic inflammatory disease characterised by lipid accumulation in the intima of 
arteries. In 1904, Leipzig Marchand was the first to use the term “atherosclerosis” to 
describe the deterioration of the arterial intima layer, which has since been widely used 
up to the present time (Tedgui and Mallat, 2006). A decade later (1913), Anichkov used 
a rabbit model of atherosclerosis to show that high levels of cholesterol was the main  
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reason for this disease (Konstantinov et al. 2006). Anichkov’s discovery facilitated 
many studies to investigate the effects of cholesterol during the progression of 
atherosclerosis. Although doubts regarding the effect of high levels of cholesterol in 
atherosclerosis still remained, accumulating evidence led the American Heart 
Association to recommend in 1961 that individuals at high risk of atherosclerosis 
change their diet in order to reduce the intake of cholesterol. However, there were still 
those who claimed that altering the diet would not cause a reduction in the disease 
(Steinberg, 1969; Ahrens, 1979; McLaren et al. 2011). In 1984, National Institute of 
Health reported that there was a significant reduction in cardiovascular endpoints when 
the level of blood cholesterol was reduced. Since that time, numerous research studies 
have shown a correlation between high plasma cholesterol levels and atherosclerosis 
(McLaren et al. 2011). 
 
1.5 Pathology of Atherosclerosis 
 
There are three morphological layers present in the normal artery: the intima, media and 
adventitia, which are shown in Figure 1.5.1. The intima, the innermost layer, is made up 
of a monolayer of ECs that is surrounded by the extracellular connective tissue matrix, 
primarily proteoglycans and collagen, and a sheet of elastic fibres, the internal elastic 
lamina (ILE). Beneath the ILE is the media, the middle layer that consists of SMCs. The 
adventitia, the outer layer, consists of connective tissues with interspersed fibroblasts 
and SMCs (Lusis, 2000; Stocker and Keaney, 2004). 
 
As shown in Figure 1.5.2, ECs activation is initiated by the various risk factors, 
particularly the accumulation of LDL and lipoprotein remnants (derived from enzymatic 
action on various lipoprotein particles) in the sub-endothelial intima (Tabas et al. 2007). 
LDL retention arises when its levels in plasma are very high, especially in certain areas 
of the arteries, such as branching or curvature (McLaren et al. 2011). As a result of 
endothelial dysfunction by numerous risk factors, a variety of chemoattractant  
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molecules are expressed by the ECs, which, in turn, attract the monocytes and T 
lymphocytes in the blood stream to recruit at the site of injury/activation. Monocytes are 
able to interact with these chemoattractant signals and migrate into the sub endothelial 
matrix. Here the monocytes differentiate into macrophages to form foam cells by taking 
up modified LDL from the sub endothelial environment. This process is called fatty 
streak formation and it is the first step in the initiation of this disease (Lusis, 2000). 
Fatty streaks subsequently “grow” into more complex lesions and form a fibrous cap 
composed of SMCs, which have migrated from the media into the intima, where they 
secrete extracellular matrix (ECM) molecules, such as elastin and collagen (Katsuda and 
Kaji, 2003; Newby, 2006). The fibrous cap continues to develop with the formation of a 
“necrotic core” due to the deposition of cholesterol and lipids from dying foam cells, to 
form a stable complex lesion (Newby, 2006). The balance between ECM synthesis and 
breakdown of the atherosclerosis plaque is responsible for the control of plaque stability 
(McLaren et al. 2011). 
 
Although the blood flow through the artery would be reduced considerably if the plaque 
became larger, leading to angina and chest pains, the formation of a blood clot 
(“thrombus”) is the most difficult complication of atherosclerosis, and can lead to 
myocardial infarction (Lusis et al. 2004). Ischemic stroke is caused if the atherosclerosis 
has an effect on the arteries that provide the brain with oxygen and blood (Harvey and 
Ramji, 2005). The above steps are reviewed in more detail in the following sections. 
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Figure 1.5.1 Structure of a normal large artery 
A large artery consists of three morphologically distinct layers. The intima, the 
innermost layer, is bounded by a monolayer of ECs surrounded by extracellular 
connective tissues matrix, primarily proteoglycans and collagen, and a sheet of elastic 
fibres, the internal elastic lamina. The media, the middle layer, consists of SMCs. The 
adventitia, the outer layer, consists of connective tissues with interspersed fibroblasts 
and SMCs. Taken from Lusis, 2000. 
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Figure 1.5.2 The development of an atherosclerotic lesionAt the site of an initial 
lesion, a fatty streak is formed when the monocytes respond to chemoattractant 
molecules that are secreted by the activated endothelium, and migrate into the 
subendothelial space, where they differentiate into macrophages. Macrophages ingest 
oxidised LDL (oxLDL) to form lipid-laden foam cells. Fatty streaks mature into a more 
advanced lesion covered with a fibrous cap that is formed as a result of SMCs’ 
migration and their expression of ECM. The foam cell secretes protease that degrades 
the ECM that, in turn, reduces the stability of the fibrous cap leading to rupture. This 
leads to the release of the lesion contents into circulation, resulting in thrombosis and 
subsequent artery blockage. Taken from McLaren et al. 2011. 
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1.6 Atherosclerosis initiation 
  
The formation of fatty streaks is one of the first characteristics of atherosclerosis in the 
intima of large and medium arteries (Tabas et al. 2007). Fatty streaks are not clinically 
significant, and may be precursors of larger atherosclerotic plaques (Tamminen et al. 
1999). Although they form an important part of the lesion, fatty streaks cannot cause 
acute events such as heart attack or stroke (Halvorsen et al. 2008). A range of risk 
factors work to activate the endothelium, change its permeability and initiate the lesion 
(Preiss and Sattar, 2007). However, it is thought that the accumulation of apoB-
containing lipoproteins, such as LDL and lipoprotein remnant, in the sub-endothelial 
intima, is the main initiator of atherosclerosis (Tabas et al. 2007; McLaren et al. 2011). 
  
LDL retention arises when the levels of plasma LDL are high, particularly in areas such 
as arterial branching or curvature (Lusis, 2000). When LDL accumulates in the sub-
endothelial intima, it undergoes various modifications, including oxidation (Ross, 
1993). Diffusion of LDL through the endothelial cells and its retention in the vessel wall 
are promoted by the interaction between matrix proteoglycans and the apoB constituent 
of LDL (Grainger et al. 1994; Lusis, 2000). It is thought that the production of 
proteoglycans increases as a result of stress on the arterial wall by the various risk 
factors (Libby et al. 2002).  
 
Normal LDL can be taken up by the LDL receptors (LDLR) that are present in most 
peripheral cell types, including macrophages. However, uptake of LDL by LDLR is 
subject to negative feed back regulation, and hence cannot make a substantial 
contribution to foam cell formation. Initial oxidation of LDL produces minimally 
modified LDL (mmLDL) that is still recognised by its native receptor. The production 
and secretion of the chemoattracting chemokine, monocyte chemoattractant protein-1 
(MCP-1) by SMCs and EC is stimulated by mmLDL to promote monocyte recruitment 
(Stocker and Keaney, 2004). 
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As shown in Figure 1.6.1, before LDL can be taken up sufficiently by a range of 
scavenger receptors expressed by macrophages in order to form foam cells, it must be 
highly oxidised. It is likely that the modification of LDL happens as a result of the 
interaction between LDL and reactive oxygen species (ROS) that are produced by 
endothelial cells and macrophages, particularly by enzymes such as myeloperoxidase 
(MPO), sphingomyelinase (SMase), and a secretory phospholipase (sPLA2). The uptake 
of modified LDL by scavenger receptors is not under negative feedback regulation and 
hence makes a major contribution to foam cell formation (Lusis, 2000).  
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Figure 1.6.1 Atherosclerosis initiation and foam cell formation 
When LDL enters the subendothelium from the blood stream, it can undergo 
modification by the retention within the matrix component in the intima. Oxidation of 
LDL takes place after its interaction with ROS produced by the endothelium via the 
action of enzymes such as MPO, SMase and sPLA2. Oxidised LDL is quickly taken up 
by macrophage scavenger receptors such as SR-A, CD36 and CD68. Scavenger receptor 
expression is regulated by cytokines such as tumour necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ). The concentration of nutrients becomes low with continued 
expansion of the lesion, which causes the cells in the middle of the lesion to die, thereby 
forming the necrotic core of the lesion. Abbreviations: LDL, low density lipoprotein; 
ROS, Reactive oxygen species; MPO, myeloperoxidase; SMase, sphingomyelinase; 
sPLA2, secretory phospholipase A2; TNF-α, Tumour necrosis factor-α; INF-γ,  
Interferon-γ and apolipoprotein E (apoE). Taken from Lusis, 2000. 
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1.7 Recruitment of monocytes/macrophages to sites of inflammation 
 
Monocytes and macrophages are present at all stages of the disease, have 
multifunctional roles in lesion progression, and make about 60-70% of cells in the 
advanced plaque (Ross, 1993; Takahashi et al. 2002). As a result of LDL retention and 
oxidation, a chronic inflammatory response is triggered. As shown in Figure 1.7.1, a 
variety of chemoattractant molecules are expressed by the activated ECs, which recruit 
the monocytes from the blood stream to the site of injury/activation (Li and Glass, 
2002). On the luminal surface of the activated endothelium, adhesion molecules, such as 
P-selectin and E-selectin, are expressed in order to initiate the rolling of monocytes. 
These selectins interact with L-selectin molecules on the surface of monocytes 
(Bobryshev, 2006). Studies have shown that apoE deficient mice, a mouse model for 
this disease, that lack adhesion molecules such as P- selectin, E-selectin and 
intercellular adhesion molecule-1 (ICAM-1), have reduced lesions (Collins et al. 2000). 
These findings therefore emphasise the important roles of these adhesion molecules in 
atherosclerosis (Collins et al. 2000). 
 
The monocytes roll across the surface of the endothelium as a result of the interaction 
between these selectins (Lusis, 2000; Li and Glass, 2002). Adhesion and migration of 
monocytes is facilitated by other molecules that are expressed by the activated 
endothelium, such as the vascular cell-adhesion molecule-1 (VCAM-1) and ICAM-1, 
which bind to integrins on recruited monocytes (Meerschaert and Furie, 1995; Li and 
Glass, 2002; McLaren et al. 2011). The diapedesis process of monocytes is further 
enhanced by the expression of chemokines and cytokines by ECs such as MCP-1, 
macrophages colony-stimulating factor (M-CSF), interleukin-8 (IL-8), TNF-α, 
macrophage inflammatory protein-1 (MIP-1) and transforming growth factor-β (TGF- 
β) (Li and Glass, 2002; Weber et al. 2007).  
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1.7.1 Chemokine MCP-1 
Chemotactic factors (or chemokines) as well as adhesion molecules mediate the entry of 
monocytes into the intima and this process can be stimulated by oxLDL, which triggers 
an inflammatory response (Li and Glass, 2002). Chemokines are small heparin-binding  
proteins (Charo and Taubman, 2004; Rot and von Andrian, 2004). About 50 human 
chemokines have been identified. The CC chemokines is the largest known family 
(Charo and Taubman, 2004). The chemokine MCP-1 (also known as CCL2) is one of 
the most broadly studied members of the CC chemokine family due to its important role 
in the recruitment of monocytes from the blood stream into the intima of the 
atherosclerotic plaque (Charo and Taubman, 2004). MCP-1 and its receptors CCR2 are 
expressed in atherosclerotic lesions (Papadopoulou et all. 2008). MCP-1 is expressed by 
many important cells in atherosclerosis such as ECs, macrophages and SMCs (Glass 
and Witztum, 2001). Studies in apoE-deficient mice have shown that the expression of 
MCP-1 is induced by oxLDL, and a reduction in the atherosclerotic plaque is noticed 
when this gene is deleted (Navab et al. 1996; Boring et al. 1998). 
 
1.7.2 Adhesion molecules 
As defined by the Gene Ontology Consortium (http://www.geneontology.org/), cellular 
adhesion molecules are "molecules expressed on the surface of a cell that mediate the 
adhesion of the cell to other cells or to the extracellular matrix" (Blankenberg et al. 
2003). The recruitment of inflammatory cells from the blood stream as well as their 
migration through the endothelium is one of the earliest stages of atherosclerosis. A 
variety of cellular adhesion molecules mediate this process when they are expressed on 
the surface of the endothelium and on circulating leukocytes in order to respond to 
many inflammatory stimuli (Blankenberg et al. 2003). When endothelial function is 
impaired, different pro-inflammatory cytokines, such as IFN-γ and TNF-α, stimulate the 
production of adhesion molecules such as ICAM-1 and VCAM-1, which leads to 
increased atherosclerosis (Catalan et al. 2012). Together with P-selectin and E-selectin, 
VCAM-1 mediates the first step in the rolling of monocytes (Nakashima et al. 1998).  
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The migration of monocyte through the endothelium is facilitated when VCAM-1 and 
ICAM-1 start adhesion by binding to integrins expressed on the surface of monocytes 
(McLaren et al. 2011). 
 
1.8 Development of an atherosclerotic lesion and smooth muscle cell migration 
 
Once the monocytes have passed through the endothelial layer by diapedesis and are 
present in the intima of the blood vessels, their differentiation can take place (Lusis, 
2000). Endothelial cells express M-CSF that mediates the differentiation of monocytes 
into macrophages (Hansson and Libby, 2006). The macrophage is a very important cell 
in the pathology of atherosclerosis due to its ability to uptake modified LDL and 
become a cholesterol-rich foam cell (Lusis, 2000). The expression of scavenger 
receptors on the surface of macrophages is induced as a result of this differentiation 
(Moore and Freeman, 2006). 
Under normal conditions the cellular uptake LDL is mediated by the LDLR (Soutar and 
Naoumova, 2007). The receptor is on the cell surface and when LDL binds, the complex 
is internalised and transported to the lysosome where the cholesterol is released for use 
in the cell. The LDLR is then recycled back to the cell surface for subsequent use 
(Soutar and Naoumova, 2007). Although the cells can take up LDL via the LDLR, this 
is under negative feedback regulation. If there is a high concentration of LDL then the 
LDLR expression will be reduced and cannot therefore contribute substantially to foam 
cell formation (Soutar and Naoumova, 2007). However, the uptake of modified LDL by 
scavenger receptors such as SR-A and CD36, is not under such negative feedback 
regulation and therefore contributes to foam cell formation due to the uncontrolled 
macrophage uptake of modified-LDL particles from the subendothelial matrix (Febbraio 
et al. 2000; Lusis, 2000; Bobryshev, 2006). It is essential that LDL should be modified, 
such as highly oxidised, for scavenger receptors to be able to recognise it. Oxidised 
LDL, but not mmLDL, is recognised by CD36 and SR-A (McLaren et al. 2011). 
Normally, the function of scavenger receptors is to take up pathogens and molecules 
derived from them, but in atherosclerosis they work to recognise oxidised LDL (Li and 
Glass, 2002). 
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SR-A is present on macrophages, SMCs as well as ECs. Although it is thought that SR-
A’s recognition of oxLDL is low, it has been found that it is responsible for about 80%  
of acetylated LDL (AcLDL) uptake (Moore and Freeman, 2006). Smaller 
atherosclerotic lesion has been observed in ApoE
−/−
 mice lacking CD36, which supports 
the role of CD36 in atherogenesis (Febbraio et al. 2000). Extensive study using mouse 
models of atherosclerosis have shown that reducing the expression of scavenger 
receptor, the atherosclerotic lesions were reduced (Lusis 2000; Bobryshev, 2006). 
 
As the disease progresses, the fatty streaks begin to mature into more complex plaques. 
A fibrous cap made up of SMCs and ECM covers the lesion. The formation of the 
fibrous cap depends on the migration and proliferation of SMCs from the media to the 
intima (Newby and Zaltsman, 1999; McLaren et al. 2011). SMCs usually reside in the 
medial layer of blood vessels where they provide strength and support to the structure of 
the vessel (Lusis, 2000). Once inside, SMCs proliferate and experience phenotypic 
modulation from quiescent, contractile phenotype to an active, synthetic form. With 
time, foam cell macrophages fill up with lipids to a point where they begin to die due to 
lake of sufficient nutrients, and start to release their contents which lead to the 
formation of a necrotic core (Dzau et al. 2002). In addition, SMCs enhance foam cell 
formation by taking up modified lipoproteins themselves and further contributing to the 
necrotic core of the atherosclerotic lesion (Li and Glass, 2002; McLaren et al. 2011). 
The intimal SMCs do not only take up modified lipoproteins but also synthesise ECM 
proteins that help with the building of the fibrous cap (Dzau et al. 2002).  
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Figure 1.7.1 Recruitment of monocytes/macrophages to sites of inflammation and 
foam cell formation 
 
LDL is subject to oxidative modification in the subendothelial space, progressing from 
mmLDL to extensive oxLDL. Monocytes attach to EC that have been induced to 
express cell adhesion molecules by mmLDL and inflammatory cytokines. Adherent 
monocytes migrate into the intima where they differentiate into macrophages. Uptake of 
oxLDL via macrophages scavenger receptors, such as SR-A and CD36, leads to foam 
cell formation. Abbreviations: mmLDL, Minimally modified low density lipoprotein; 
oxLDL, Oxidised low density lipoprotein; SR-A: Scavenger receptor A; ICAM-1, 
Intercellular adhesion molecule-1; VCAM 1, vascular cell adhesion molecule-1; MCP-
1, Monocyte chemoattractant protein-1; CCR2, Chemokine receptor-2, M-CSF, 
Macrophages colony stimulating factor. Taken from Glass and Witztum, 2001.  
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1.9 Plaque rupture 
  
A stable, complex lesion is formed with the continuous progression of the fibrous cap, 
which now encloses the new enlarged necrotic core (McLaren et al. 2011). When the 
atherosclerotic plaque matures into a more complex lesion, it can be described either as 
a stable plaque or that susceptible to rupture. Stable plaques have a thick fibrous cap, 
smaller lipid core and few inflammatory cells within the shoulder regions. On the other 
hand, plaques with a thin fibrous cap, high lipid content in its core and a large number 
of T-cells and macrophages in the shoulder regions are considered to be unstable and 
“rupture-prone” (van der Wal and Becker, 1999; Stocker and Keaney, 2004). The 
balance between ECM synthesis and breakdown is very important for the stability of the 
plaque (Newby, 2006; McLaren et al. 2011). Inflammatory cells produce cytokines such 
as IFN-γ that mediates the degradation of ECM (Hansson et al. 2002; Lusis et al. 2004). 
There are several factors that affect plaque rupture. Some of the factors that influence 
stability are cytokines, protease expression, and the proliferation, migration and 
apoptosis of SMCs (Lusis, 2000). An important factor in thinning of the fibrous cap is a 
reduction in the production of the ECM as a result of apoptosis of SMCs. During the 
progression of the lesion, cytokines such as IFN-γ are secreted which affects 
macrophages and causes them to undergo apoptosis (Lusis, 2000, Lusis et al. 2004, 
McLaren and Ramji, 2009), leading to an increase in the size of the necrotic core. As a 
result, physical pressure will be exerted on the fibrous cap, causing further apoptosis of 
SMCs (George and Johnson, 2010). Since IFN-γ also has the ability to prevent the 
synthesis of collagen in SMCs, any collagen that has been degraded cannot be replaced 
(Libby et al. 2002; Lusis et al. 2004). In addition, macrophages can produce proteolytic 
enzymes within the plaque that degrade the collagen of the fibrous cap, which results in 
its weaking and making it more likely to rupture (Libby et al. 2002). The proteolytic 
enzymes include matrix metalloproteinases (MMPs)(Newby, 2008). MMPs are a family 
of matrix-degrading enzymes. In some cases specific MMPs promote stability of plaque 
by stimulating VSMC migration, and in other cases they degrade ECM components and 
induce apoptosis of VSMC, and therefore reduce plaque stability. They are therefore 
considered to be a key feature of advanced atherosclerosis (Newby, 2006; McLaren et 
al. 2011). 
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As shown in Figure 1.5.2, the blockage of lumen by an atherosclerotic plaque does not 
cause the acute symptoms of this disease. It is when the plaque ruptures and the 
thrombotic reaction starts that the clinical complications of atherosclerosis begins to 
manifest (McLaren et al. 2011). 
 
1.10 Cytokines 
 
Stanley Cohen was the first to introduce the term cytokines in 1974. They are a large 
group of proteins with molecular weight ranging from 8 to 40kDa (Tedgui and Mallat, 
2006). Lymphokines and monokines are the original names of cytokines, and were used 
to denote their cellular origins (Balkwill and Burke, 1989). Thereafter, the term 
cytokines was used and is the best description since the majority of the inflammatory 
cells have the ability to synthesise cytokines, which, in turn, cause changes in gene 
expression in target cells and regulation of the progression of the atherosclerotic plaque 
(Dinarello, 2000). For example, during the progression of atherosclerosis, cytokines are 
known to control the migration/proliferation of SMCs from the media into the intima 
(Lusis, 2000). In addition, the expression of key genes implicated in the disease 
pathology, such as chemokines, adhesion molecules and scavenger receptors, is also 
regulated by cytokines (Tedgui and Mallat, 2006). 
 
 Over 50 cytokines are known and include interleukins, the tumour necrosis factors 
(TNF), interferons (IFN), colony stimulating factors (CSF), transforming growth factors 
(TGF) and chemokines (Dinarello, 2000; Tedgui and Mallat, 2006). The importance of 
cytokines comes from their ability to regulate the immune response (Tedgui and Mallat, 
2006). A variety of cytokines have been reviewed and studied, and they have been 
found to be expressed at different stages of atherosclerosis (Tedgui and Mallat, 2006). 
The major sources of cytokines in atherosclerosis are macrophages and infiltrating T-
lymphocytes. They are classified according to their pro- or anti-inflammatory actions. 
The levels of pro-inflammatory cytokines have been observed to be high atherosclerotic 
plaque (Harvey and Ramji, 2005; Halvorsen et al. 2008).  
 
 
Hadeel Altuwayjiri                                                                           1008122 
 
 22 
 
The ability of cytokines to mediate their actions in the disease comes from their 
interaction with specific receptors on the surface of the cells (Singh and Ramji, 2006). 
The cytokines that are highly expressed in the atherosclerotic plaque are shown in 
Figure 1.10.1 along with whether they act as pro-or anti-inflammatory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10.1 The cytokines that are highly expressed in the atherosclerotic plaque. 
IL-1, TNF-α and IFN-γ act as a pro-atherogenic manner whereas IL-10, IL-33 and TGF-
β are anti-atherogenic. Both pro- and anti-atherogenic roles have been found for certain 
cytokines like IL-6 and IL-17A. Adapted from Singh and Ramji, 2006. 
 
Pro-inflammatory cytokines are expressed at high levels in the initial stage of 
atherosclerosis (Kapoor et all. 2006). For example, IL-1 accelerates atherosclerosis 
through wide ranging effects including promoting the proliferation of SMCs. It can also 
induce the expression of MMPs (Kapoor et all. 2006; Tedgui and Mallat, 2006). Anti-
inflammatory cytokines serve to limit inflammatory responses often through their 
ability to suppress the expression of pro-inflammatory cytokines (Dinarello, 2000). 
TGF-b is expressed in many cell types including EC, SMCs, monocytes/macrophages, 
platelets and T-cells in relation to atherosclerosis (Singh and Ramji, 2006). It has been 
shown previously in our laboratory and elsewhere that macrophage apoE expression is  
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increased by TGF-b stimulation (Singh and Ramji 2006; Zuckerman et al. 1992). In 
apoE-/- mice fed on a high fat diet, the accumulation of macrophage-derived foam cells  
in atherosclerotic plaques was reduced significantly when treatment with IL-33 
(McLaren et al. 2010b) 
 
Although the effect of classical cytokines, such as IFN-γ, in atherosclerosis and on gene 
expression in macrophages is well understood, this is not the case for many cytokines, 
such as IL-37 and recently identified cytokines whose receptors are expressed in these 
cells such as IL-15, IL-20 and IL-22. 
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1.10.1 IFN-γ 
The human interferon (IFN) family is categorised into two major types. Type I consists 
of IFN-α, IFN-β, IFN-ε,, IFN-κ, IFN-ω and IFN-ν and type II consists of only IFN-γ 
(Pestka, 2007). Type I IFNs share common structure and are synthesised by most cell 
types (Meager, 1998). On the other hand, type II IFN has a single member with a 
different molecular structure from the type I IFNs and functions through a separate 
receptor (IFN-γR) (Mire-Sluis and Thorpe 1998; Schroder, Hertzog et al. 2004). IFN-γ, 
the most studied pro-inflammatory cytokine, is a type II member of the IFN family of 
cytokines (McLaren and Ramji, 2009). It is highly expressed in atherosclerotic lesions 
by various cells including monocytes/macrophages and T lymphocytes (Whitman et al. 
2000). The main action of IFN-γ is mediated through the Janus Kinase (JAK)/ Signal 
Transducer and Activator of Transcription (STAT) pathway (Figure 1.10.1.1) (McLaren 
and Ramji, 2009). IFN-γ accelerates atherosclerosis in mouse models of this disease 
(Schonbeck et al. 1997; McLaren et al. 2011) by modulating several steps. For example, 
IFN-γ contributes to the thinning of the fibrous cap by upregulating the expression of 
MMPs, which work to inhibit the proliferation of SMCs and reducing their production 
of collagen ( Halvorsen et al. 2008; George and Johnson, 2010). Expression of 
chemokins such as MCP-1 is also induced by the cytokine (Boisuert, 2004; Charo et al, 
2004). However, evidence from in vitro cell culture model systems suggests that the 
role of IFN-γ is more complicated, since both pro- and anti-atherogenic properties have 
been observed (McLaren and Ramji, 2009). Thus, it has been shown to inhibit SR-A 
and CD36 expression in human monocyte-derived macrophages (McLaren and Ramji, 
2009). This suggested a potential role of IFN-γ in reducing foam cell formation. 
However, other work in THP-1 macrophages and primary cultures has found that IFN-γ 
induced uptake of oxidised and acetylated LDL and induces the expression of several 
scavenger receptors  (Geng and Hansson, 1992; McLaren and Ramji, 2009). 
 
IFN-γ has also been shown to have an effect on ECs in atherosclerosis. For example, 
IFN-γ induces the expression of both VCAM-1 and ICAM-1 in ECs, which are very 
important adhesion molecules in the early stage of developing fatty streaks. This 
suggests a pro-atherogenic role for it in relation to the endothelium (Cybulsky et al. 
1993; Li et al. 1993; Valente et al. 1998; Chung et al. 2002) 
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Figure 1.10.1.1 JAK/STAT1 signalling in response to IFN-γ. The binding of IFN-γ to 
its cognate, cell surface receptor involves dimerisation of the two IFN-γ receptor (IFN-
γR) subunits, made up of IFN-γR1: IFN-γR2 pairs, and results in the activation of two 
bound tyrosine kinases, JAK1 and JAK2, by tyrosine phosphorylation. Once the JAKs 
become activated, or tyrosine phosphorylated, they mediate tyrosine phosphorylation of 
the IFN-γ receptor tails through their catalytic, C-terminal kinase domain. Latent 
STAT1 monomers, located in the cytoplasm are recruited to the receptor tails, via their 
Src homology 2 (SH2) domains and become phosphorylated on tyrosine 701. The 
tyrosine phosphorylated STAT1 monomers dimerise forming a STAT1:STAT1 
homodimer which can translocate to the nucleus and bind to the interferon gamma 
activation sequence (GAS) elements in the promoters of IFN target genes. Tyrosine 
phosphorylated STAT1 homodimers can also be phosphorylated at serine 727 by 
kinases like phosphatidylinositol 3-kinase (PI3K) and P38 mitogen-activated protein 
kinase which enhances their transcriptional capacity. Abbreviations: IFN-γ, interferon-γ; 
JAK, Janus kinase; p38 MAPK, p38 mitogen-activated protein kinase; PI3K, 
phosphatidylinositol 3-kinase; SH2, Src-homology 2; STAT1, Signal transducer and 
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activator of transcription 1; GAS, the interferon gamma activation sequence. Taken 
from McLaren and Ramji. 2009. 
 
1.10.2 IL-37 
IL-37 is a member of the IL-1 family and was formerly called IL1F7 (Bufler, 2011). 
The way IL-37 functions remains unclear as limited research has been carried out on 
this cytokine. The production of pro-inflammatory cytokines was  inhibited when IL-37 
was expressed in macrophages (Boraschi et al. 2011). In addition the expression of 
human IL-37 downregulated inflammation in  mouse models system (Bufler, 2011; 
Banchereau et al. 2012). IL-37, which was first identified in 2000, was therefore 
thought to be an anti-inflammatory cytokine, and is known to bind to the IL-18α 
receptor (Moschen et al. 2011).  
 
1.10.3 IL-15 
IL-15 is a member of the IL-2 family (Benczik and Gaffen, 2004). It is expressed by a 
variety of cells including monocytes, macrophages and EC, and has been shown to 
promote atherosclerosis in a mouse model of this disease (Oppenheimer-Marks et al. 
1998; Krishnaswamy et al. 1999; Musso et al. 1999; van Es et al. 2010). IL-15 
contributes to promote the recruitment of T-cells to the site of inflammation in 
atherosclerotic lesion (Wuttge et al. 2001). It has a unique receptor (IL-15Rα), which 
has also been found to be expressed on the surface of macrophages (Giri et al. 1995). 
Van Es et al. (2010) showed that the expression of MCP-1 and TNF-α was induced 
significantly when mouse macrophages (RAW264.7 cells) were treated with IL-15, but 
there was no effect on the expression of adhesion molecules such as ICAM-1 and 
VCAM-1. They also observed a 75% reduction in plaque size with a surprising 2-fold  
increase of macrophage content when the mice (LDL definition mice) were given oral 
vaccination against IL-15, suggesting a pro-inflammatory role of this cytokine in the 
mouse model (van Es et al. 2010). A decade ago, a study in humans and apoE
−/−
 mice 
had also found that atherosclerotic lesions contain IL-15 (Houtkamp et al. 2001; Wuttge 
et al. 2001). However, the role of IL-15 in human macrophages is poorly understood 
despite its receptors being expressed on these cells. 
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1.10.4 IL-20 
IL-20 is a member of the IL-10 family. It is expressed by macrophages and has been 
shown to promote atherosclerosis in a mouse model of this disease (von der Thusen et    
al. 2003; Chen et al. 2006). It acts via receptors that consist of IL-20R1 and IL-20R2 
(Ait-Oufella et al. 2011). The main source of IL-20 in an atherosclerotic lesion is 
macrophages (Chen et al. 2006). A study in premenopausal obese women showed that 
when compared to matched normal weight controls, the levels of IL-20 were higher in 
obese women and these levels were reduced with weight loss (Maiorino et al. 2010). 
This suggests that IL-20 is also involved in obesity which predisposes to atherosclerosis 
(Maiorino et al. 2010). However, the role of IL-20 in human macrophages is poorly 
understood despite their receptors being expressed on these cells. 
 
1.10.5 IL-22 
IL-22 (previously named ILTIF) is an IL-10 cytokine family member, that is produced 
by Th17 cells and is expressed at high levels in inflamed tissues (Fickenscher et al. 
2002). However, is not clear whether other cell types might also produce IL-22 
(Fickenscher et al. 2002; Gu et al. 2008; Aujla and Kolls, 2009). IL-22 acts through the 
IL-22R receptor (Aujla and Kolls, 2009). However, its role in atherosclerosis and 
macrophages particularly of human origin, has not been studied despite the cognate 
receptors being expressed on these cells (Dhiman et al. 2009). 
 
1.11 Aims of the project 
 
As detailed above, atherosclerosis, the underlying cause of heart disease and stroke is a 
major killer in the western world. It is an inflammatory disorder of arteries regulated by 
cytokines (McLaren et al. 2011). Cytokines mediate the development of the 
atherosclerotic plaque, and they affect all stages of the disease. Cytokines have central 
roles in the control endothelial cell permeability, recruitment of monocytes to the 
activated endothelium, expression of adhesion molecules and scavenger receptors, 
migration of SMCs and induction of apoptosis (Tedgui and Mallat, 2006). As regards 
cytokines, a substantial amount of information is available on classical cytokines, such 
as IFN-γ, TNF-α, IL-1 and TGF-β (Ait-Oufella et al. 2011). However, very little is  
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known about the more recently identified cytokines. Recent studies in 2010 in our 
laboratory on more recently identified cytokines, such as IL-33 and tumour necrosis 
factor-like protein 1A (TL1A), have provided new insight into their roles in 
macrophages in relation to atherosclerosis (McLaren et al. 2010a; McLaren et al. 
2010b). Investigation of the role of more recently identified cytokines such as IL-37, IL-
15, IL-22 and IL-20 in human macrophages was therefore the major focus of research in 
this project.  
 
The initial aim of this project was to investigate the effect of these cytokines (IL-37, IL-
15, IL-20 and IL-22) on the expression of key genes in macrophages implicated in the 
control of inflammation, such as MCP-1 and ICAM-1 (see Figure 1.11.1). IFN-γ was 
used as a positive control since it is widely studied and its pro-atherogenic effects on the 
expression of these genes is well documented (Chung et al. 2002; Harvey and Ramji, 
2005). The project also aimed to confirm key findings at the levels of protein expression 
using Western blot analysis. The effect of cytokines on the uptake of modified LDL by 
macrophages and foam cell formation was also investigated.  
 
The human THP-1 cell line was used as a model system for human macrophages. When 
stimulated with phorbol esters, such as phrobol 12-myristate 13-acetate (PMA), THP-1 
cells mimic the monocyte-derived macrophages by becoming adherent to glass or 
plastic, exhibiting a macrophage-like morphology and expressing macrophage 
differentiation markers (Kohro et al. 2004). THP-1 macrophages have been used widely 
to investigate macrophage gene expression in relation to atherosclerosis, particularly the 
effects of cytokines, because numerous responses observed in them have been found to 
be conserved with primary macrophages and in vivo (Auwerx, 1991; Worley et al. 2003; 
Kohro et al. 2004; McLaren et al. 2010a; McLaren et al. 2010b; Salter et al. 2011).  In 
addition, some experiments were carried out using mouse RAW264.7 cells in order to 
compare key findings with human THP-1 macrophages and to delineate the possible 
existence of species-specific regulatory mechanisms. RAW264.7 cells do not require 
PMA activation because they are adherent, differentiated macrophages. The cells have 
previously been used to investigate the role of IL-15 and IFN-γ along with the  
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regulation of mouse macrophage gene expression in relation to atherosclerosis (Kota et 
al. 2006; van Es et al. 2010). 
 
 
Figure 1.11.1 Genes used in this study and their role in atherosclerosis progression   
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CHAPTER 2 
Materials and Methods 
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2.1 Materials 
 
Table 2.1.1 lists the materials used during the course of this study together with the 
suppliers from which they were purchased. 
 
Table 2.1.1 Materials and Suppliers 
Materials Suppliers 
Deoxyribonucleotidetriphosphate (dNTPs); 
Moloney murine leukemia virus reverse 
transcriptase (MMLV RT); RNasin 
ribonuclease inhibitor; Random 
hexamer primers 
Promega, UK 
Ampicillin; Bromophenol blue; PMA; 
Tween20; SYBR Green; X ray film; 
DMSO; Tween 20; RIPA buffer 
Sigma, UK 
Agarose; PCR reaction buffer Bioline, UK 
10x TBE National Diagnostics, UK 
Spin column RNA Miniprep Kit NBS biologicals 
THP-1 and RAW 264.7 cell lines ECACC, UK 
Tissue culture flasks; 6-well plates; 12- 
well plates; Cell scrapers; 50ml Falcon 
tubes. 
Greiner Bio One, UK 
IL-37; 1L-15; IL-20; IL-22; IFN-γ; mIL-15; 
m IFN-γ 
Peprotech, UK 
PCR  primers Sigma Genosys, UK 
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EDTA; Ethanol; Glycerol; Industrial 
methylated spirit; Sodium dodecyl sulfate 
SDS; Tri-soduim citrate; Tris buffer; Filter 
papers 
Fisher scientific, UK 
Sterile 0.22µm filters; PVDP membrane Millipore, UK 
I Block; CDP Star reagent Applied Biosystems, UK 
NuPage™ Novex Gel Tank system; 
Blotting module; SDS-PAGE gels, MOPS 
running buffer; Transfer buffer; 
RPMI 1640 with GlutaMAX™; Penicillin; 
Streptomycin, 
Foetal calf serum; 2-mercaptoethanol, 
1kb DNA molecular markers; See Blue 
protein markers 
Invitrogen, UK 
Goat anti-rabbit alkaline phosphatase 
(AP); Goat anti-mouse AP; Rabbit anti-
goat AP 
Santa Cruz Biotechnology, USA 
PCR tubes; PCR plates; PCR seals ELKay, UK 
BCA protein assay Pierce, UK 
Acetylated LDL (AcLDL) Intracell, USA 
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2.2 Methods 
 
2.2.1 Preparation of solutions and glassware 
 
Solutions and glassware were autoclaved for 20-30 min at 121°C (975kPa) as necessary 
 
2.2.2 Cell culture techniques 
  
THP-1 is a human monocytic leukaemia cell line that can be differentiated into 
macrophages using PMA. Differentiated THP-1 cells display many of the properties and 
characteristics of human monocyte-derived macrophages and are therefore a useful 
model for studying the properties of macrophages, including cell signalling and gene 
expression in relation to atherosclerosis (Auwerx, 1991). After addition of phorbol 
esters the cells become adherent to tissue culture flasks. 
 
RAW 264.7 are a murine macrophage cell line established from a tumour induced by 
the Abelson murine leukaemia virus (Raschke et al. 1978). They are used routinely to 
study mouse macrophage function and gene expression and can also be transfected 
efficiently with exogenous DNA (Stacey et al. 1996; Hartley et al. 2008). RAW264.7 
cells are adherent to tissue culture flasks and dishes. 
 
 2.2.2.1 Maintenance of cell lines in culture 
THP-1 and RAW 264.7 cells were grown in RPMI-1640 with GlutaMAX™ (stabilised 
L-glutamine). The medium was supplemented with 10% (v/v) heat-inactivated (at 56°C 
for 30min) foetal calf serum (HI-FCS) containing penicillin (100U/ml) and 
streptomycin (100μg/ml) (pen/strep). Both HI-FCS and penicillin/streptomycin were 
passed through a 0.2μm sterile filter prior to addition to the medium. Cells were 
maintained in a humidified incubator (37˚C) with a 5% (v/v) CO₂ atmosphere. Cells 
between passages 2 and 6 were used for experiments.  
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2.2.2.2 Counting cells 
A haemocytometer (Neubauer chamber) was used to count THP-1 and RAW264.7 cells. 
After centrifugation (100g for 5min), cells were re-suspended in an appropriate volume 
of culture medium containing 10% (v/v) HI-FCS. The haemocytometer was covered 
with a precision ground coverslip, and then 7μl of cell suspension was used and the 
numbers of cells in the 5 x 5 grid were counted. The number of cells/ml was calculated 
by multiplying the number of cells in the grid by 10
4. The appropriate volume of cells 
was diluted using fresh medium and seeded into tissue culture flasks or plates. 
 
2.2.2.3 Sub-culturing of cells 
THP-1 cells were sub-cultured when they were approximately 60% confluent (0.6 x 10
6 
cells/ml). The cells were transferred into a polypropylene tube (Falcon tubes) and 
centrifuged at 100g for 5min. The medium was aspirated and the cells were re-
suspended in pre-warmed medium containing 10% (v/v) HI-FCS and pen/strep. Cells 
were placed in new tissue culture flasks and grown up at 37°C in a humidified, 5% (v/v) 
CO2 incubator. Cells were usually split in a 1:15 ratio so that growth back up to 60% 
confluency occurred in approximately one week. For experiments, cells between 
passage 2 and 6 were used.  
 
RAW264.7 cells were sub-cultured when they reached approximately 80% confluency 
on the surface of the culture dish. The cells were removed from the surface of the dish 
by scraping. Some of the resulting cell suspension was transferred into a new dish at a 
ratio of 1:25 with fresh pre-warmed medium supplemented with 10% (v/v) HI-FCS and 
pen/strep. Cells were grown up at 37°C in a humidified, 5% (v/v) CO2 incubator. 
 
2.2.2.4 Preserving and storing of cells 
THP-1 and RAW264.7 cells were preserved at -80°C or in liquid nitrogen for 
longer time periods. Only early passage cells (up to passage 3) were used for storage. 
Prior to freezing, cells were centrifuged at 100g for 5min and re-suspended in HI-FCS 
containing 10% (v/v) DMSO. Cells at a density of approximately 5 x 10⁶ cells/ml were 
aliquoted into 1ml cryoampoules and stored at -80°C overnight before being transferred 
to liquid nitrogen.  
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2.2.2.5 Thawing frozen cells 
Cells from liquid nitrogen were defrosted by placing them in a water bath at 37°C. Cells 
were transferred to a polypropylene tube containing 10% (v/v) HI-FCS and centrifuged 
at 100g for 5min. After re-suspension into fresh medium containing 10% (v/v) HI-FCS, 
the cells were plated out into tissue culture flasks and incubated at 37ºC with 5% (v/v) 
CO₂. 
 
2.2.2.6 Treatment of cells with PMA and cytokines 
THP-1 cells were differentiated with 0.16μM PMA for 24hr before cytokine treatment. 
Cytokines were added directly to the culture medium and the cells were incubated at 
37ºC with 5% (v/v) CO₂ for the required time.  
 
2.2.2.7 Setting up experiments for cytokine stimulation 
For real-time quantitative PCR (RT-qPCR), cells (500,000 for THP-1 and 600,000 for 
RAW264.7) were placed in each well of a 12-well plate and supplemented with 1ml of 
culture medium with 10% (v/v) HI-FCS. THP-1 cells were first differentiated using 
0.16µM PMA for 24hr before cytokines treatment as below. For RAW264.7 cells, the 
medium was first aspirated and replaced, and then the cytokines were added for 3hr and 
24hr, as required. The cytokines used in this study along with their concentrations are 
shown in Table 2.2.2.1. The concentrations are based on previous studies (Chen et al. 
2006; Kleemann et al. 2008; van Es et al. 2010). For Western blot analysis, 1x10
6
 cells 
were added to each well of a 6-well plate with 1ml medium containing 10% (v/v) HI-
FCS. The addition of PMA and cytokines was the same as for RTq-PCR. For 
experiments involving macrophage cholesterol uptake and foam cell formation, 500,000 
cells were added to each well of a 12-well plate with 1ml medium containing 10% (v/v)  
HI-FCS. Cells were then stimulated with PMA for 24hr. After that, cells were treated 
with cytokines or vehicle and 10mg/ml of AcLDL.  
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Table 2.2.2.1 : Cytokines used and their concentrations 
Cytokines Concentration 
h IFN-γ 1000 U/ml 
m IFN-γ 1000 U/ml 
h IL-37 100 ng/ml 
h IL-15 100 ng/ml 
m IL-15 100 ng/ml 
h IL-20 100 ng/ml 
h IL-22 100 ng/ml 
 
2.3 RNA/DNA techniques 
 
2.3.1 Isolation of RNA 
 
Following incubation with cytokines, the RNA was isolated using a RNA Miniprep Kit 
(NBS Biologicals). The medium was aspirated from the cells, and they were washed 
with 1ml of phosphate buffered saline (PBS). After that, cells were lysed by the addition 
of 350µl of Buffer Lysis-DR provided in the kit. The lysate was then either collected 
and transferred to the gDNA Eliminator Colum in a 2 ml collection tube (provided in 
the kit), and then centrifuged at 9,000g for 1min at room temperature, or was transferred 
into 2 ml collection tubes and saved at -80˚C for later use. The rest of the protocols 
were carried out according to the manufacturer’s instructions. The RNA concentration 
and quality (OD 260:280 ratio) was determined using a Nanodrop ND2000 
spectrophotometer. 
 
2.3.2 RT-qPCR 
 
Reverse transcription-polymerase chain reaction consists of two steps: 
1. The synthesis of cDNA using reverse transcriptase; 
2. PCR using gene-specific primers under optimised conditions. 
 
 
Hadeel Altuwayjiri                                                                           1008122 
 
 37 
 
2.3.2.1 Reverse transcriptase 
A mixture containing 1µg RNA (0.5 µg if the amount of isolated RNA was low), 
random hexamer primers (200pmol) and sterile water made up to a final volume of 
13.5µl was incubated at 72˚C for 5 min and immediately cooled on ice. The following 
reagents were then added to the reaction:  
1µl of dNTP mixture (10 mM each of deoxyadenosine 
triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate 
(dGTP) and deoxythymidine triphosphate (dTTP); 
4µl of 5x Molony murine leukaemia virus (M-MLV) buffer; 
0.5µl (50U/μl) of recombinant RNase inhibitor; and  
1µl (200U/μl) of M-MLV reverse transcriptase. 
 
The total reaction mixture was incubated at 37˚C for 1 hr and the reaction terminated by 
incubation at 92˚C for 2 min. Synthesised cDNA was diluted by adding 80μl (or 30μl if 
0.5μg RNA was used) of RNase-free water and then stored at -20˚C.  
 
2.3.2.2 Polymerase chain reaction 
Once the cDNA had been manufactured, it could be used to optimise condition for PCR, 
if necessary, and to determine regulation of expression of specific genes. The primer 
sequences that were used are shown in Table 2.3.3 and 2.3.4, human and mouse primers 
respectively. These were either based on validated sequences previously used for semi-
quantitative PCR in the laboratory or sourced from previous publications or from 
websites called Primer Bank or QPCR. In the latter cases, attempts were made where 
ever possible to choose sequences that gave optimal product size of around 100pb. The 
composition of the PCR reactions used in the RT-PCR reaction also shown in Table 
2.3.2 and the reaction conditions are shown in Table 2.3.5 for human and 2.3.6 for mice. 
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2.3.2.2.1 Q-PCR 
A Q-PCR reaction was set up using the SYBER® GREEN JumpStart™ Taq 
Readymix™ for quantitative PCR (Sigma-Aldrich). The composition of the reaction is 
detailed in Table 2.3.1. The reactions were then “run” using an Opticon 2 PCR machine 
(MJ Research). The reagents were mixed and added into a 96 well plate and the 
program was set according to the optimised PCR conditions (Tables 2.3.5 and 2.3.6). 
The Q-PCR data were analysed using the comparative Ct (ΔΔCt) method (Livak and 
scmittgen 2001). The output of RT-qPCR reaction shows the number of PCR cycles 
against the increasing fluorescence. This is known as amplification point. The ΔΔCt 
method relies on measuring the number of reaction cycles it takes for the amplification 
plot crosses the threshold level (Ct value) within the exponential phase of the 
amplification (Livak and scmittgen 2001). The CT values were then collected from the 
computer and analysed on Microsoft Excel using the ∆∆CT method (Ginzinger, 2002). 
The Ct value of the gene of interest was compared relative to the Ct value of a control 
housekeeping gene to normalise the data (Livak and scmittgen 2001). The ∆∆Ct method 
relies on two assumptions, firstly that the expression of the housekeeping gene does not 
vary under experimental conditions and secondly, that the PCR efficiencies for each 
primer set used in the analysis are similar (Ginzinger 2002). The reaction conditions are 
shown in Tables 2.3.5 for human and 2.3.6 for mouse.   
 
Table 2.3.1: The composition of a 25µl Q-PCR reaction 
Reagent Amount (µl) 
SYBER® GREEN Ready mix (Sigma Aldrich) 12.5 
Forward Primer (200pmol) 0.5 
Reverse Primer (200pmol) 0.5 
Water 10.5 
cDNA 1 
Total 25 
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Table 2.3.2 PCR reaction set up used for semi-quantitative RT-PCR reactions 
Reagent Amount 
Forward Primer (200pmol) 0.5μl 
Reverse Primers (200pmol) 0.5μl 
dNTPs  1μl 
Buffer 5μl 
Taq  0.25μl 
Sterile Water 32.75μl 
cDNA 10μl 
 
Table 2.3.3 Human PCR primers for analysis of gene expression in THP-1 
macrophages 
Primer 
Name  
Forward  Primer 
(5’-3’) 
Reverse Primer 
(5’-3’) 
Size of 
Product 
(bp) 
References 
GAPDH GAAGGTGAAGGT 
CGGAGTC 
GAAGATGGTGAT 
GGGATTTC 
226 (Vandesompele 
et al. 2002) 
MCP-1 CATTGTGGCCA 
AGGAGATCTG 
CTTCGGAGTTT 
GGGTTTGATT 
91 (Locati et al. 
2002) 
ICAM-1 ACGCTGAGCTC 
CTCTGCTACTC 
GGGCAGGATGA 
CTTTTGAGG 
162 (NILESH et al. 
2010) 
 
Table 2.3.4 Mouse PCR primers for analysis of gene expression in RAW264.7 cells 
Primer 
Name 
Forward  Primer 
(5’-3’) 
Reverse Primer 
(5’-3’) 
Size of 
Product 
(bp) 
References 
 β-Actin TGGAGAAGAGCT 
ATGAGCTGCCTG 
GTGCCACCAGAC 
AGCACTGTGTTG 
202 (McLaren et 
al. 2010b) 
 MCP-1 CTGGATCGGAA 
CCAAATGAG 
CGGGTCAACT 
TCACATTCAA 
95 (Locati et 
al. 2002) 
 ICAM-1 CAGTCCGCTG 
TGCTTTGAGA 
CGGAAACGAA 
TACACGGTGAT 
75 (Lei et al. 
2009) 
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Table 2.3.5: Amplification condition for Q-PCR with human primer sequences 
PCR Step GAPDH MCP-1  ICAM-1 
Initial Melting 95˚C for 5 min 95˚C for 5 min 95˚C for 5 min 
Annealing  60˚C for 60 sec 63˚C for 60 sec 63˚C for 60 sec 
Extension 72˚ for 60 sec 72˚ for 60 sec 72˚ for 60 sec 
Melting 95˚C for 30 sec 95˚C for 30 sec 95˚C for 30 sec 
Final Extension 72˚ for 10 min 72˚ for 10 min 72˚ for 10 min 
Number of cycles 35 35 35 
 
Table 2.3.6: Amplification conditions for Q-PCR with mouse primer sequences 
PCR Step β-Actin MCP-1 ICAM-1 
Initial Melting 95˚C for 5 min 95˚C for 5 min 95˚C for 5 min 
Annealing 58˚C for 60 sec 59˚C for 60 sec 60˚C for 60 sec 
Extension 72˚ for 60 sec 72˚ for 60 sec 72˚ for 60 sec 
Melting 95˚C for 30 sec 95˚C for 30 sec 95˚C for 30 sec 
Final Extension 72˚ for 10 min 72˚ for 10 min 72˚ for 10 min 
Number of cycles 35 35 35 
 
 
2.3.2.3 Agarose Gel Electrophoresis 
Size fractionation of PCR products was carried out by agarose gel electrophoresis. For 
this, 1.5% (w/v) gels were made up with agarose dissolved in 1 x TBE buffer. The 
agarose solution was warmed in the microwave until the agarose had dissolved followed 
by the addition of 0.5μg/ml ethidium bromide. Stock solutions for gel electrophoresis 
are shown below in Table 2.3.7. 
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Table 2.3.7 Composition of reagents used in gel electrophoresis  
Reagent Composition 
10 x TBE 0.89M Tris borate, 890M boric acid and 20M EDTA, pH 
8.0 
5x DNA loading 
dye 
1 x TBE. 50% (v/v) glycerol and 2.25% (w/v) 
bromophenol blue 
   
DNA samples were prepared with 5μl of DNA loading dye and electrophoresis was 
carried out in 1 x TBE buffer at 100-150V for around 30-60 min using a horizontal 
gel unit (Fisherbrand). The size of the PCR products was compared to low 
molecular weight DNA ladder. DNA was visualised under UV light using a 
Syngene Gel Documentation system. 
 
 
2.4 Western Blot analysis 
 
2.4.1 Cell lysis 
Following stimulation with PMA for 24hr, and then cytokine or vehicle treatment for 
the required time, the medium was aspirated from the wells and the cells were washed  
with 1ml of ice cold PBS. The cells were then lysed with 50µl of RIPA buffer (Sigma). 
The lysate was transferred to a 2ml collection tube and the mixture then boiled at 100˚C 
for 5min. The lysate was then ready for loading onto a pre-cast SDS-PAGE gel 
(Invitrogen). 
 
2.4.2 Protein concentration 
The concentration of total protein was determined using the BCA protein assay kit 
(Pierce). A standard curve was produced for each assay using suitable dilution of a 
2mg/ml bovine serum albumin (BSA) solution to give final concentrations of 5µg/ml, 
10µg/ml, 15µg/ml, 20µg/ml and 25µg/ml. Samples were diluted in water in ratios of 
1:300. Each sample (150µl) was analysed in duplicate and was placed in the wells of a 
96-well micro-titre plate followed by the addition of 150µl Micro BCA protein assay 
reagent (Pierce). The plate was covered with a pre-cut Transparent Microplate Sealer 
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(Greiner Bio One) and left in the incubator at 37˚C for 2hr. A Model 680 Microplate 
Reader (Biorad) was used to measure the absorbance of each sample at a wavelength of 
570nm. The protein concentration of each sample was then calculated from the standard 
curve.  
 
2.4.3 Gel electrophoresis and transfer of proteins to membrane 
SDS- polyacrylamide gel electrophoresis (SDS-PAGE) was carried out using NuPage 4-
12% Bis-Tris gels (Invitrogen). The tank was filled with NuPAGE MOPS SDS Running 
Buffer (Invitrogen) and the gels were placed within the tank. Equal amount of protein 
sample was added to each well, along with a protein standard, and the gel was subjected 
to electrophoresis for 80min at 150V, 400mA. Following electrophoresis, the stacking 
gel was cut away and the separating gel equilibrated in NuPAGER® Transfer Buffer 
(Table 2.4.1). Immobulin-P PVDF membrane (0.45μm pore size, Millipore) was cut to 
the size of the gel and activated in pure 100% (v/v) methanol for 5min. The membrane  
 
was placed on top of the gel and both were sandwiched between Whatman 3MM paper 
and sponge pads, which had also been soaked in the NuPAGER® Transfer Buffer 
(Table 2.4.1).  The entire set up was then placed in a blotting cassette and transfer 
carried out at 30V, 300mA for 85min. Transfer efficiency was checked at this stage by 
staining the PVDF membrane with Ponceau S solution. 
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2.4.4 Immuno-detection of proteins 
Following blotting, the membrane was removed from the sandwich and washed with 
PBS-Tween (Table 2.4.1) for 5 min and then incubated in I-BT solution (Table 2.4.1) 
shaking for 1hr in order to block any potential non-specific interactions of the 
antibodies to the membrane. After removal of the I-BT solution the primary antibody 
was diluted in more I-BT (Table 2.4.2) and then added to the membrane and left 
overnight shaking at 4˚C. Following the primary antibody incubation, the membrane 
was then washed three times with PBS-Tween (5min each). After the wash steps were 
complete, the secondary antibody was diluted also in I-BT (Table 2.4.2) and then added 
to the membrane and left for 1hr shaking at room temperature. The membrane was 
again washed three times with PBS-Tween (5min each). Different exposures were then 
developed using a Kodak film placed inside a light resistant X-ray cassette. The film 
was developed using Agfa film processor and developer. A detection reagent (CDP-
Star) was added according to the manufacturer’s instructions (Applied Biosystems) to 
the membrane before developing the membrane using a Kodak film.  
 
Table 2.4.1 Composition of stock solutions used for protein analysis by SDS-PAGE 
and Western blotting 
 
Solution  Composition 
NuPAGER MOPS SDS Running 
Buffer (x20) 
 
50mM 3-(N-morpholino) propane 
sulfonic acid (MOPS), 50 mM Tris 
Base, 0.1% (w/v) SDS, 1 mM EDTA, 
pH 7.7 
NuPAGER Transfer Buffer 50mM Bis-tris propane, 50mM Bicine, 
20% (v/v) methanol 
I-BT solution 500ml PBS-Tween, 1gram Tropix I-
Block, 500ml of 5% (v/v) sodium azide 
PBS-Tween  10L ddH20, 100 PBS tablets, 20ml 
Tween20 
Ponceau S 0.1% (w/v) Ponceau S, 5%(v/v) acetic 
acid, ddH2O 
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Table 2.4.2 Antibodies and dilutions used for Western blotting 
Protein Primary 
Antibody 
1˚ antibody 
dilution 
Secondary 
Antibody 
2˚ antibody 
Dilution 
Protein 
Size 
ICAM-1 Rabbit 1:200 Goat Anti 
Rabbit (AP) 
1:5000 110KDa 
MCP-1 Goat 1:500 Rabbit Anti 
Goat (AP) 
1:5000 14KDa 
β-actin Mouse 1:10,000 Goat Anti  
Mouse (AP) 
1:5000 42KDa 
 
2.4.5 Analysis of western blots 
The densities of bands from immunoblots were analysed using GeneTools software 
(Syngene). All experimental values were normalised to the control β-actin.  
 
2.5 Uptake of AcLDL by macrophages 
 
The THP-1 cell line (5x10⁵ cells) was placed in each well of a 12-well plate and 
supplemented with 1ml of RPMI-1640 with 10% (v/v) HI-FCS and pen/strep. The cells 
were differentiated using 0.16μM PMA for 24hr prior to starting the assay. The cells 
were then incubated for 24hrs with 10μg/ml AcLDL in the presence of vehicle or IFN-γ 
(1,000U/ml) or IL-15 (100ng/ml) (representative experiments in the absence of AcLDL 
were also included for comparative purposes). After 24hr incubation, the medium was 
aspirated from the wells and the cells were washed with 1ml of ice cold PBS about 6 to 
7 times. For lipid extraction, 500μl of ice-cold hexane:isopropanol (2:3, v/v) was added 
into the wells and left to incubate on ice for 15min, and then the lysate was transferred 
into 0.5ml Eppendorf tubes and left to evaporate at room temperature over night. Lipids 
were then resuspended in hexane:igenal (9:1, v/v) and used for the Amplex red 
cholesterol assay.  
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2.5.1 Protein extraction 
After removal of lipids, the proteins were extracted by adding 500μl of 0.2% (v/v) 
NaOH, and incubated at 37°C in a humidified, 5% (v/v) CO2 incubator for 3hr. Protein 
concentration was determined using the Micro BCA protein assay kit as described in 
Section 2.4.2 
 
2.5.2 Amplex red cholesterol assay 
Samples were prepared in a black, 96-well plate. A standard curve was produced by 
diluting 2μl of cholesterol reference standard (provided in the kit) in 500μl of 1x 
reaction buffer (Table 2.5.1) to produce cholesterol concentration of 0 to 8μg/ml. Then, 
50μl of the cholesterol-containing samples were diluted in 200μl of 1x reaction buffer 
(Table 2.5.1) (1:5, v/v). Diluted samples (50µl) and standards were added into separate 
wells of a black 96-well plate. To measure the total cholesterol, 50µl of the Amplex® 
Red reagent (300μM)/Horseradish peroxidise (HRP) (2U/ml)/cholesterol oxidase 
(2U/ml)/cholesterol esterase (2U/ml) working solution (prepared according to the 
manufacturer’s instructions (Invitrogen)) was added into each well containing the 
diluted samples and standards. To measure the free cholesterol, another working 
solution was prepared without the cholesterol esterase and 50µl was added into separate 
wells containing the diluted samples. The plate was covered with a pre-cut Transparent 
Microplate Sealer (Greiner Bio One) and left in the incubator at 37˚C for 30min. The 
fluorescence was measured in a fluorescence microplate reader using a Flostar 
OPTIMA. Cholesterol ester content was calculated by subtracting the free cholesterol 
value from the total cholesterol value of each sample. 
 
2.5.1 Amplex Red reagent Stock solutions: 
Stock solution Concentration 
1x Reaction Buffer 5ml of 5x reaction buffer (provided in the Kit) with 20ml 
of deionised water 
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2.6 Statistical analysis of data 
Data sets were tested for normality using the Shapiro-Wilk test. Statistical analysis was 
performed using Student's t-test for single comparisons (two-tailed, paired) or one-way 
ANOVA for multiple comparisons with Tukey’s post-hoc test, where homogeneity of 
variance was met; or Welch’s test of equality of means with Games-Howell post-hoc 
analysis. [* P < 0.05; ** P < 0.01; *** P < 0.001, and NS indicates not significant]. 
The details of which are given in the Appendices.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hadeel Altuwayjiri                                                                           1008122 
 
 47 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
RESULTS 
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3.1 Introduction 
 
As described in the General Introduction, atherosclerosis is a chronic inflammatory 
disease caused by the accumulation of cholesterol within the walls of large and medium 
arteries (Lusis, 2000). Several cytokines are expressed in atherosclerotic lesions and 
their role in disease has been highlighted by studies in mouse model systems (Kleemann 
et al. 2008). The importance of cytokines comes from their ability to regulate the 
immune response (Tedgui and Mallat, 2006). 
 
Many genes have been shown to play a critical role in the development of 
atherosclerosis (Tedgui and Mallat, 2006). Numerous studies have focused on the role 
of chemokines and adhesion molecules on the progression of this disease. They are both 
notably present in the initial stages of plaque formation (Cybulsky et al. 2004). MCP-1 
is a chemokine that belongs to the large CC chemokine family. Many cells associated 
with the progression of atherosclerosis, such as ECs, macrophages and SMCs, have 
been found to express MCP-1 and other chemokines (Aiello et al. 1999; Charo and 
Taubman, 2004). Cushing et al. (1990) showed that the expression of MCP-1 in the 
initial stage of atherosclerosis is induced by mmLDL (Stocker and Keaney, 2004). 
MCP-1 is implicated in the recruitment of monocytes from the blood stream to the 
surface of the ECs at this early stage (Charo and Taubman, 2004). The role of MCP-1 in 
the disease has been identified from studies using mouse model systems; for example, 
MCP-1 deficiency in murine model decreased the progression of atherosclerotic plaque 
development(Charo and Taubman, 2004), while the lesion formation and deposition of 
macrophages was increased when MCP-1 was overexpressed in the bone-marrow-
derived cells of apoE
−/−
 mice (Aiello et al. 1999). ICAM-1, on the other hand, is an 
adhesion molecule belonging to the immunoglobulin superfamily. ICAM-1 is expressed 
on the surface of the EC, and contributes to the adhesion and migration of monocytes to 
the subendothelium space (Fotis et al. 2012). Studies of apoE deficient mice have 
indicated that the atherosclerotic lesion development is reduced with ICAM-1 
deficiency (Kitagawa et al. 2002). 
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In relation to cytokines and atherosclerosis, although the effect of classical cytokines, 
such as IFN-γ, on macrophage gene expression is well understood, this is not the case  
for many cytokines, such as IL-37, and more recently identified cytokines whose 
receptors are expressed in these cells such as IL-15, IL-20 and IL-22. The initial aim of 
this project was therefore to investigate the effect of more recently identified cytokines 
on the expression of key genes in macrophages implicated in the control of 
inflammation and foam cell formation during atherosclerosis. IFN-γ is a widely studied 
cytokine in our laboratory and its action in atherosclerosis has been widely investigated; 
therefore, it was used as a positive control (Harvey et al. 2007; Harrirs et al. 2008; Li et 
al. 2010). 
 
The overall experimental strategy and the three parameters that were analysed for IL-15, 
IL-20, IL-22 and IFN-γ are shown in Figure 3.1.1 Firstly, the effect of the cytokines on 
the mRNA expression of MCP-1 and ICAM-1, two major markers of inflammation, was 
determined by RT-qPCR. The studies on Western blot analysis and modified LDL 
uptake were restricted to IFN-γ (positive control) and IL-15 (the only cytokine that 
affected the expression of MCP-1 and ICAM-1). A slightly different strategy was 
adopted for IL-37 (see Figure 3.1.2). Previous studies have shown that the expression of 
IL-37 in macrophages or epithelial cells inhibited the production of pro-inflammatory 
cytokines such as IL-1α, IL-6, TNF-α and MIP2-α stimulated by lipopolysaccharide 
(LPS) (Nold et al. 2010). On the other hand, silencing of endogenous IL-37 in human 
blood cells increased the abundance of these cytokines in response to LPS (Nold et al. 
2010). We therefore determined whether pre-incubation of THP-1 macrophages with 
IL-37 affected gene expression by the pro-inflammatory cytokine IFN-γ. Because the 
potential time of IL-37 action, if any, was not known, two pre-incubation time points 
were chosen, 3hr and 24hr.   
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Human THP-1 
Monocytes  
RAW264.7 
24hr 
PMA 
Macrophages 
Incubate for 3hr (early time point) or 
24hr (late time point) with vehicle or 
IL-15, IL-20, IL-22 or IFN-γ. 
Cytokine addition 
Incubate for 3hr (early time point) 
with vehicle or IFN-γ, or 24hr (late 
time point) with vehicle or IL-15.  
Cytokine addition 
mRNA expression of two 
markers of inflammation,  
 MCP-1 and ICAM-1. 
 
RT-qPCR 
 
Protein expression of  
MCP-1 and ICAM-1 (IFN-
γ and IL-15 only).  
 
Western blot 
 Macrophage cholesterol 
uptake and foam cell 
formation using Amplex 
Red cholesterol assay kit 
(IFN-γ and IL-15 only). 
 
Modified LDL uptake 
 
 
 
Figure 3.1.1 Overall experimental strategy and the three parameters that were 
analysed  
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Figure 3.1.2 RT-q-PCR strategy for IL-37 
 
 
Human THP-1 
Monocytes  
24hr 
PMA 
Macrophages 
Human THP-1 
Monocytes  
24hr 
PMA 
Macrophages 
3hr with vehicle or IFN-γ.  3hr with vehicle or IFN-γ.  
3hr with vehicle or IL-37.  24hr with vehicle or IL-37.  
RT-qPCR RT-qPCR 
Hadeel Altuwayjiri                                                                           1008122 
 
 52 
 
3.2 The effect of cytokines on MCP-1 and ICAM-1 mRNA expression in THP-1 
macrophages 
 
As detailed in the General Introduction, the THP-1 cell line was chosen as a model for 
human macrophages because of conservation of responses to those observed in human 
primary cultures and in vivo (Auwerx, 1991; Worley et al. 2002; Kohro et al. 2004; 
Salter et al. 2011; Michael et al. 2012). The human THP-1 cell line was first 
differentiated into macrophages by incubation with PMA for 24hr.  Figure 3.2.1 shows 
the morphology of THP-1 monocytes and macrophages. After 24hr stimulation with 
0.16μM PMA, the THP-1 monocytes adhere to the bottom of the flask and had 
morphological characteristics of macrophages. THP-1 macrophages were then 
stimulated with different human cytokines (or vehicle control) for 3hr or 24hr. These 
two time points were chosen for this study rather than a detailed time course analysis 
because previous studies in the laboratory have shown that gene expression by 
cytokines occurs in two phases: early (typically 3hrs) and late (typically 24hrs). 
 
The mRNA expression of target genes was studied using RT-qPCR. Q-PCR is a PCR 
based technique that is able to quantify the amount of DNA being synthesised in each 
cycle of the reaction. The advantage of this technique is that the starting amount of 
DNA in the sample can be accurately determined from the CT values from the Q-PCR 
reaction. The method that was used to determine the starting amount of DNA was the 
ΔΔCT method (Ginzinger, 2002). The cytokines that were used during this study were 
human IFN-γ, IL-37, IL-15, IL-20, IL-22, mouse IFN-γ and mouse IL-15 (Table 
2.2.2.1). The expression of MCP-1 and ICAM-1 was normalised to the house-keeping 
gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for human cells and β-
Actin for mouse cells. Melting curve analysis was performed to confirm amplification 
of a single product (Figure 3.2.2). 
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Figure 3.2.1 Morphology of THP-1 monocytes and macrophages THP-1 monocytes (1 x 
10
6
 cells) were cultured in 6-well tissue culture flask and either left untreated (top) or 
incubated for 24h (bottom) with 0.16μM PMA. The cells become adherent to tissue 
culture flask after incubation with PMA. Photos were taken on x20 magnification. 
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Figure 3.2.2 Melting curve analysis for Human primers RTq-PCR was 
performed for MCP-1, ICAM-1 and GAPDH. The graphs show that a single major 
amplification product was produced from human primers A: MCP-1, B: ICAM-1 
and C: GAPDH. 
 
 
Hadeel Altuwayjiri                                                                           1008122 
 
 55 
 
We first examined the effect of different cytokines (IL-15, IL-20, IL-22 and IL-37) on 
MCP-1 and ICAM-1 mRNA expression in THP-1 macrophages using IFN-γ as a 
positive control. 
 
3.2.1 IFN-γ 
As detailed above, the cytokine IFN-γ was used as a positive control as previous 
research in our laboratory and that of the others have shown that it induces the 
expression of both MCP-1 and ICAM-1 (Chung et al. 2002; Harvey and Ramji, 2005; 
Li et al. 2010). RT-qPCR results for human THP-1 macrophages stimulated with IFN-γ 
for 3hr and 24hr are shown in Figures 3.2.1.1 and 3.2.1.2 respectively. As expected, a 
significant increase in the expression of MCP-1 and ICAM-1 was observed.  
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Figure 3.2.1.1 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
THP-1 macrophages. THP-1 monocytes were differentiated into macrophages using 
PMA and then incubated for 3hr with vehicle (Con) or IFN-γ (1,000U/ml). Total RNA 
was isolated and subjected to RT-qPCR. The graph shows the fold change in mRNA 
expression  (mean ± SD) in relation to the control, vehicle-treated cells (arbitrarily 
assigned as 1) from four independent experiments, samples in duplicate. A, MCP-1; B, 
ICAM-1. Statistical analysis was performed using the Student's t-test, ** P < 0.01; *** 
P < 0.001.  
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Figure 3.2.1.2 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
THP-1 macrophages at 24hr. THP-1 monocytes were differentiated into macrophages 
using PMA and then incubated for 24hr with vehicle (Con) or IFN-γ (1,000U/ml). Total 
RNA was isolated and subjected to RT-qPCR. The graph shows the fold change in 
mRNA expression (mean ± SD) in relation to the control, vehicle-treated cells 
(arbitrarily assigned as 1) from four independent experiments, samples in triplicate. A, 
MCP-1; B, ICAM-1. Statistical analysis was performed using the Student's t-test, ** P < 
0.01; *** P < 0.001.  
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3.2.2 IL-15, IL-20 and IL-22 
Having confirmed the positive action of IFN-γ on MCP-1 and ICAM-1 mRNA 
expression in THP-1 macrophages, the action of IL-15, IL-20 and IL-22 was next 
investigated. As shown in Figure 3.2.2.1, all three cytokines had no statistically 
significant effect on the expression of MCP-1 or ICAM-1 at incubation period of 3hr. 
Similarly, IL-20 and IL-22 had no effect on the expression of MCP-1 or ICAM-1 at the 
24hr time point (Figure 3.2.2.2). In contrast, IL-15 significantly attenuated MCP-1 
expression at 24hr (Figure 3.2.2.2). In addition, although the effect of IL-15 on ICAM-1 
mRNA levels at this time point was not significant, a trend of reduced expression was 
seen (Figure 3.2.2.2). 
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Figure 3.2.2.1 IL-15, IL-20 and IL-22 have no effect on MCP-1 and ICAM-1 
mRNA expression in THP-1 macrophages at 3hr. THP-1 monocytes were 
differentiated into macrophages using PMA and then incubated for 3hr with vehicle 
(Con) or IL-15 (100ng/ml), IL-20 (100ng/ml) or IL-22 (100ng/ml). Total RNA was 
isolated and subjected to RT-qPCR. The graph shows the fold change in mRNA 
expression (mean ± SD) in relation to the control, vehicle-treated cells (arbitrarily 
assigned as 1) from four independent experiments, samples in duplicate. A, MCP-1; B, 
ICAM-1. Statistical analysis was performed using one-way ANOVA with Welch's test 
of equality of means with Games–Howell post-hoc analysis. No significant result was 
obtained.    
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Figure 3.2.2.2 IL-15 attenuates MCP-1 mRNA expression in THP-1 macrophages 
at 24hr. THP-1 monocytes were differentiated into macrophages using PMA and then 
incubated for 24hr with vehicle (Con) or IL-15 (100ng/ml), IL-20 (100ng/ml) or IL-22 
(100ng/ml). Total RNA was isolated and subjected to RT-qPCR. The graph shows the 
fold change in mRNA expression (mean ± SD) in relation to the control, vehicle-treated 
cells (arbitrarily assigned as 1) from four independent experiments, samples in 
triplicate. A, MCP-1; B, ICAM-1. Statistical analysis was performed using one-way 
ANOVA with Welch's test of equality of means with Games–Howell post-hoc analysis. 
* P < 0.05; NS indicates not significant.    
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3.2.3 IL-37 
The next cytokine that was studied was IL-37. For this, the cells were first pre-treated 
with IL-37 or vehicle for 3hr or 24hr and then incubated with vehicle or IFN-γ for 3hr 
(see Figure 3.1.2 for experimental strategy).  In experiments involving pre-incubation of 
the cells with IL-37 or vehicle for 3hr (Figure 3.2.3.1), IFN-γ induced the expression of 
both MCP-1 and ICAM-1 mRNA though this failed to reach significance probably due 
to relatively large SD in these experiments. Incubation with IL-37 alone had no effect 
on MCP-1 mRNA expression and reduced that for ICAM-1 though this was not 
statistically significant. More importantly, the IFN-γ-induced levels of MCP-1 or 
ICAM-1 mRNA were not significantly affected by pre-incubation of the cells with IL-
37. 
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Figure 3.2.3.1 Pre-incubation of THP-1 macrophages with IL-37 for 3hr has no 
effect on MCP-1 and ICAM-1 mRNA expression induced by IFN-γ. THP-1 
monocytes were differentiated into macrophages using PMA and then incubated for 3hr 
with vehicle (Con and IFN-γ (1,000U/ml)) or IL-37 (100ng/ml) (IL-37 and IFN-γ+Il-
37). The cells were then treated for 3hr with IFN-γ (IFN-γ and IFN-γ+IL-37) or vehicle 
(Con and IL-37). Total RNA was isolated and subjected to RT-qPCR. The graph shows 
the fold change in mRNA expression (mean ± SD) in relation to the control, vehicle-
treated cells (arbitrarily assigned as 1) from three independent experiments, samples in 
duplicate. A, MCP-1; B, ICAM-1. Statistical analysis was performed using one-way 
ANOVA with Welch's test of equality of means and Games–Howell post-hoc analysis. 
NS indicates not significant.    
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For experiments involving pre-incubation of the cells with IL-37 or vehicle for 24hr 
(Figure 3.2.3.2), IFN-γ induced the expression of both MCP-1 and ICAM-1 mRNA 
though this failed to reach significance for MCP-1 probably because of relatively large 
SD in this case. Incubation with IL-37 alone had no effect on MCP-1 mRNA expression 
and reduced that for ICAM-1 though this was not statistically significant. In addition, 
the IFN-γ-induced levels of MCP-1 or ICAM-1 mRNA were not significantly affected 
by pre-incubation of the cells with IL-37. Overall, these results suggest that pre-
incubation of THP-1 macrophages with IL-37 does not inhibit IFN-γ-induced 
expression of both MCP-1 and ICAM-1 mRNA expression. 
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Figure 3.2.3.2 Pre-incubation of THP-1 macrophages with IL-37 for 24hr has no 
effect on MCP-1 and ICAM-1 mRNA expression induced by IFN-γ. THP-1 
monocytes were differentiated into macrophages using PMA and then incubated for 
24hr with vehicle (Con and IFN-γ (1,000U/ml)) or IL-37 (100ng/ml) (IL-37 and IFN-
γ+Il-37). The cells were then treated for 3hr with IFN-γ (IFN-γ and IFN-γ+IL-37) or 
vehicle (Con and IL-37). Total RNA was isolated and subjected to RT-qPCR. The graph 
shows the fold change in mRNA expression (mean ± SD) in relation to the control, 
vehicle-treated cells (arbitrarily assigned as 1) from three independent experiments, 
samples in duplicate. A, MCP-1; B, ICAM-1. Statistical analysis was performed using 
one-way ANOVA with Welch's test of equality of means and Games–Howell post-hoc 
analysis. *** P < 0.005; NS indicates not significant. 
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3.3 The effect of IL-15 on MCP-1 and ICAM-1 expression in mouse macrophages  
 
Previous studies had shown that IL-15 induced the expression of MCP-1 in RAW264.7 
macrophages without affecting that of ICAM-1(van Es et al. 2010). However, in the 
present study, IL-15 inhibited MCP-1mRNA expression in THP-1 macrophages (Figure 
3.2.2.2). To investigate whether this was likely to be because of species-specific 
differences, experiments were carried out on mouse macrophages (RAW264.7 cell line). 
In addition, ICAM-1 expression was included in the analysis. 
 
3.4 Optimisation of PCR conditions 
 
The conditions for PCR amplification with human primers were already established in 
our laboratory. However, this was not the case for mouse primers and hence the PCR 
conditions to investigate the regulation of expression of mouse (m) MCP-1 and ICAM-1 
by cytokines were first optimised in this study. Primer sequences for mMCP-1 and 
mICAM-1 were taken from previously published papers (see Table 2.3.4) and ordered 
(Sigma Genosys). The amount of reagents for PCR reactions are well established in our 
laboratory but the annealing temperature of the primers clearly varies depending on the 
sequence. Therefore, for each set of primers two annealing temperatures were tested to 
find the optimum that gave maximal output of the amplification product. These studies 
showed that the optimal annealing temperature with the mMCP-1 and mICAM-1 
primers were 59ºС and 60ºС respectively. The results with RT-PCR using these 
optimised conditions are shown in Figure 3.4.1. As expected a single product of the 
expected size was obtained.  
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Figure 3.4.1 Gel electrophoresis showing the PCR products from reactions using 
the optimised conditions RNA was extracted from 24hr PMA-differentiated THP-1 
macrophages that were treated with vehicle for 3hr (UT for IFN-γ(1,000U/ml)) or 24hr 
(UT for IL-15 (100ng/ml)) or the cytokines for this time period.  PCR products for 
mMCP-1 and mICAM-1 are shown. The amount of all PCR reagents was the same in 
each reaction but the annealing temperatures were as follows: mMCP-1= 59ºС and 
mICAM-1= 60 ºС. The size of the expected PCR products are A: mMCP-1= 95bp and 
B: mICAM-1= 75bp. M shows the lane where molecular size markers were loaded. 
 
The expression of MCP-1 and ICAM-1 was normalised to the house-keeping gene β-
actin. Melting curve analysis was performed to confirm amplification of a single 
product (Figure 3.4.2). 
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Figure 3.4.2 Melting curve analysis for Mouse Primers RTq-PCR was performed for 
MCP-1, ICAM-1 and β-Actin. The graphs show that a single major amplification 
product was produced from mouse primers A: MCP-1, B: ICAM-1 and C: β-actin. 
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The RNA from RAW264.7 macrophages that were treated with vehicle (control) or 
IFN-γ (positive control) or IL-15 was subjected to RT-qPCR. As above, the incubation 
period with IFN-γ was 3hr. For IL-15, the incubation period was 24hr because at only 
this time point was a reduction in MCP-1 mRNA expression observed. The results are 
shown in Figures 3.4.3 and 3.4.4 respectively. 
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Figure 3.4.3 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
RAW264.7 macrophages. The cells were incubated for 3hr with vehicle (Con) or IFN-
γ (1,000U/ml). Total RNA was isolated and subjected to RT-qPCR. The graph shows 
the fold change in mRNA expression (mean ± SD) in relation to the control, vehicle-
treated cells (arbitrarily assigned as 1) from three independent experiments, samples in 
duplicate. The mRNA levels were normalised to the house-keeping gene, β-actin. A, 
MCP-1; B, ICAM-1. Statistical analysis was performed using the Student's t-test, ** P < 
0.01.  
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Figure 3.4.4 IL-15 induces the expression of MCP-1 and ICAM-1 mRNA in 
RAW264.7 macrophages. The cells were incubated for 24hr with vehicle (Con) or IL-
15 (100ng/ml). Total RNA was isolated and subjected to RT-qPCR. The graph shows 
the fold change in mRNA expression (mean ± SD) in relation to the control, vehicle-
treated cells (arbitrarily assigned as 1) from three independent experiments, samples in 
duplicate. A, MCP-1; B, ICAM-1. Statistical analysis was performed using the Student's 
t-test, * P < 0.05; ** P < 0.01.   
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As expected, IFN-γ significantly induced the mRNA expression of MCP-1 and ICAM-1 
when RAW264.7 cells were stimulated with this cytokine (Figure 3.4.3). Consistent 
with the previous study (van Es et al. 2010), IL-15 also significantly induced the 
expression of MCP-1 mRNA in RAW264.7 macrophages (Figure 3.4.4). In addition, in 
contrast to the finding in this study, IL-15 also significantly induced the expression of 
ICAM-1 mRNA in these cells (Figure 3.4.4).  
 
Given that from the recently identified cytokines, only IL-15 affected the expression of 
MCP-1 and ICAM-1 mRNA, its action on two additional parameters (protein 
expression and modified LDL uptake) was studied in THP-1 macrophages. Similar to 
RT-qPCR, IFN-γ was included as a positive control. 
 
3.5 Western blot analysis 
 
Western blot analysis was performed to investigate whether changes in mRNA 
expression, as identified by RT-qPCR, correlated with changes in protein expression. 
For this, protein extracts were prepared from THP-1 macrophages treated with IFN-γ 
(positive control) or IL-15 (the only cytokine from IL-15, IL-20 and IL-22 that affected 
gene expression). As with studies on mRNA expression, the incubation period was 3hr 
with IFN-γ and 24hr with IL-15. Vehicle-treated cells at these time points were included 
as controls. Membranes were re-probed with β-actin to ensure equal loading. Because of 
time limitation and as the THP-1 monocytes tend to divide slowly; these experiments 
were only carried out twice so it was not possible to carry out any statistical analysis.  
 
As shown in Figure 3.5.1, a single band for expected size of ICAM-1 (110kDa) and β-
actin (42KDa) were obtained. Densitometric analysis from two independent 
experiments showed that, similar to mRNA expression, the steady state levels of ICAM-
1 eas also induced. Having confirmed the positive action of IFN-γ, the effect of IL-15 
was next investigated. 
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Figure 3.5.1 IFN-γ induces the expression of the ICAM-1 protein in THP-1 
macrophages. The cells were incubated with vehicle (- or Con) or IFN-γ (+ or IFN-γ) 
(1,000U/ml) for 3hr. Total cellular proteins were then subjected to Western blot analysis 
using antisera against ICAM-1 and β-actin, as indicated. The image is representative of 
two independent experiments. The graph shows average fold change in protein 
expression of ICAM-1 (normalised to β-actin) in relation to the vehicle control 
(arbitrarily assigned as 1) from two independent experiments.  
 
Figure 3.5.2 shows that similar to the trend in mRNA expression (Figure 3.2.2.2), IL-15 
inhibited the steady state level of the ICAM-1 protein. 
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Figure 3.5.2 IL-15 inhibits the expression of the ICAM-1 proteins in THP-1 
macrophages. The cells were incubated with vehicle (- or Con) or IL-15 (+ or IL-15) 
(100ng/ml) for 24hr. Total cellular proteins were then subjected to Western blot analysis 
using antisera against ICAM-1 or β-actin, as indicated. The image is representative of 
two independent experiments. The graph shows average fold change in protein 
expression of ICAM-1 (normalised to β-actin) in relation to the vehicle control 
(arbitrarily assigned as 1) from two independent experiments. 
 
The MCP-1 protein is heavily glycosylated and previous studies on mouse macrophages 
showed multiple cross-reactive bands in the range of 14-30kDa corresponding to 
various glycosylation products (Zhang et al. 1996; Harvey et al. 2007). However, when 
Western blot analysis was carried out on human THP-1 macrophages (Figure 3.5.3), the 
background was generally higher and multiple immunoreactive products were obtained. 
Although an immune-reactive band of the expected size (14 KDa) was seen the others, 
particularly higher molecular weight products, represent non-specific interactions of the 
antibody. Although the high background makes it difficult to make major conclusions, it 
is interesting to note that densitometric analysis of the immunoreactive product of 
expected size (indicated by an arrow in Figure 3.5.1) from two independent experiment 
shows increased levels when the cells were incubated with IFN-γ and decreased levels 
when the cells were treated with IL-15 (Figure 3.5.2). 
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Figure 3.5.3 The effect of IFN-γ or IL-15 on MCP-1 protein expression in THP-1 
macrophages. The cells were incubated with vehicle (or Con) or IFN-γ (1,000U/ml) 
and or IL-15 (100ng/ml) for the indicated period of time. Total cellular proteins were 
then subjected to Western blot analysis using antisera against MCP-1 or β-actin, as 
indicated. The graph shows average fold change in the levels of the immunoreactive 
product (normalised to β-actin) in relation to the vehicle control (arbitrarily assigned as 
1) from two independent experiments. 
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3.6 Modified LDL uptake. 
 
Acetylated LDL is commonly used for monitoring macrophage foam cell formation in 
vitro as it is efficiently taken up by the cells (Goldstein et al. 1979; Geng and Hansson, 
1992; McLaren et al. 2010b; Michael et al. 2012). The assay involves incubation of the 
cells with AcLDL (10μg/ml) and either vehicle or cytokine. Cells incubated in the 
absence of AcLDL were also included for comparative purposes. Again, IFN-γ was 
used as a positive control as it is known to promote foam cell formation (McLaren and 
Ramji, 2009). Previous time course analysis had shown that the optimum uptake of 
AcLDL by cytokines occurs at 24hr so this was chosen as the incubation period for both 
cytokines (Michael et al. 2012). The uptake of AcLDL and its subsequent metabolism 
was monitored by analysing the intracellular levels of total cholesterol, free cholesterol 
and cholesteryl esters. Unfortunately, negative values were obtained for cholesteryl 
esters for unknown reasons so the levels of only total- and free-cholesterol could be 
determined. A slight increase in intracellular level of both total cholesterol and free 
cholesterol was observed when the cells were incubated with vehicle in the presence of 
AcLDL compared to cells treated with vehicle alone though this failed to reach 
statistical significance (Figure 3.6.1). In addition, no significant effect was observed 
with cells treated with either IFN-γ or IL-15 (Figure 3.6.1).    
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Figure 3.6.1 The effect of cytokines on AcLDL uptake by THP-1 macrophages. 
THP-1 macrophages were incubated for 24hrs with 10μg/ml AcLDL (+) in the presence 
of vehicle alone (C+) or IFN-γ (1,000U/ml) or IL-15 (100ng/ml) as indicated (cells 
without AcLDL (Shown as C-) were also included for comparative purposes). The 
intracellular levels of free cholesterol and total cholesterol were then determined 
statistical analysis was carried out using one way ANOVA with Welch's test of equality 
of means and Games–Howell post-hoc analysis. No significant change was observed. 
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The experiments above were carried out using complete medium and it was therefore 
possible that lipids and lipoproteins present in FCS might have been taken up by the 
cells and be responsible for only a marginal increase in intracellular cholesterol level 
when the cells were incubated in the presence of AcLDL compared to its absence 
(Figure 3.6.1). Because the majority of previous studies were carried out in medium 
containing 0.2% (v/v) fatty acid free BSA (Michael et al. 2012), it was decided to carry 
out an experiment using this condition and IFN-γ as a positive control. In addition, the 
buffers, reagents and enzymes were changed to see if positive values for cholesteryl 
esters were obtained. As shown in Figure 3.6.2, the intracellular levels of total 
cholesterol, free cholesterol and cholesteryl ester were increased in the presence of 
AcLDL and this was further elevated by IFN-γ. This confirms the pro-foam cell 
properties of this cytokine (Figure 3.6.2). Future studies will seek to extend the analysis 
to IL-15.  
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Figure 3.6.2 IFN-γ promotes foam cell formation. THP-1 macrophages were 
incubated for 24hrs with 10μg/ml AcLDL in the absence or the presence of IFN-γ 
(1,000U/ml) (cells without AcLDL were included for comparative purposes). The 
intracellular levels of total cholesterol, free cholesterol and cholesteryl esters were 
determined as described in Materials and Methods. The data is from a single experiment 
because of time limitations.  
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4.1 Introduction 
 
Atherosclerosis is a progressive, chronic inflammatory condition of the vasculature 
that causes around 40% of all deaths in the Western population. The disease is 
governed by various environmental and genetic risk factors (Lusis et al. 2004). It is 
now widely recognised that macrophages play a critical role in the development and 
progression of atherosclerosis (Gui et al. 2012).  At the initial stage of the disease, 
cytokines are responsible for the recruitment of monocytes from the blood stream to 
the activated endothelium, where they differentiate into macrophages (Gui et al. 
2012). Cytokines also regulate other stages in the disease such as foam cell 
formation, cell death, migration and proliferation of smooth muscle cells, and 
plaque rupture.  
 
Regulation of gene expression by cytokines is of crucial importance in the field of 
atherosclerosis because they modulate the inflammatory signals that drive the 
disease process. In the context of the disease, cytokines are often grouped according 
to their pro- or anti-inflammatory action. It has been observed that the level of pro-
inflammatory cytokines is higher than anti-inflammatory cytokines in 
atherosclerotic lesions (Harvey and Ramji, 2005; Halvorsen et al. 2008), and this 
might be responsible for the progression of the disease. Anti-inflammatory 
cytokines include IL-10, IL-4, TGF-β and IL-33. Pro-inflammatory cytokine include 
TNF-α, IFN-γ, IL-1, IL-12 and IL-17 (Tedgui and Mallat, 2006). Since monocytes 
and macrophages are main contributors to the pool of cytokines in the plaque, and 
are regulated by them to play critical roles in the disease, they are useful cells to 
study inflammation and atherosclerosis (Lusis, 2000). 
 
The studies presented in this work investigated the effect of more recently identified 
cytokines on the expression of key genes in macrophages implicated in the control 
of inflammation during atherosclerosis. Three parameters were analysed (Figure 
3.1). Cytokines used for this study were the classical cytokine IFN-γ whose action is 
well known and which was used as a positive control, and more recently identified  
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cytokines such as IL-37, IL-15, IL-20 and IL-22. For the purpose of this study, 
THP-1 cells were used as an vitro model system to study the mRNA expression of 
two markers of inflammation, namely, MCP-1 and ICAM-1, protein expression and 
uptake of modified LDL leading to foam cell formation. 
 
4.2 Action of IFN-γ on the mRNA expression of MCP-1 and ICAM-1 
IFN-γ plays a complex role in atherosclerosis with both pro- and anti-atherogenic 
actions being reported though most of in vivo studies point to a pro-atherogenic role 
(McLaren and Ramji, 2009). IFN-γ has been shown to influence many features of 
atherosclerosis such as foam cell formation and plaque development (McLaren and 
Ramji, 2009). It has also shown to increase foam cell formation in THP-1 
macrophages and primary cultures (McLaren and Ramji, 2009). Previous studies in 
our laboratory and those of the others has shown that IFN-γ reduced the expression 
of efflux genes such as apoE and ABCA-1 where the expression of uptake genes 
such as SR-A was increased (Geng and Hansson, 1992; McLaren and Ramji, 2009). 
This suggested a pro-atherogenic role for IFN-γ in foam cell formation. IFN-γ is 
also known to induce adhesion molecules in SMCs and vascular ECs and by this 
action contributes to atherosclerosis development (Chung et al. 2002). The action of 
IFN-γ on the expression of MCP-1 and ICAM-1 was initially investigated by RT-
qPCR experiments using two time points (3hr and 24hr). Consistent with previous 
results from our laboratory and other, IFN-γ was found to induce the expression of 
MCP-1 and ICAM-1 at both time point (Figure 3.2.1.1 and 3.2.1.2) (Chung et al. 
2002; Harvey and Ramji, 2005; Li et al. 2010). The effect of IFN-γ on the 
expression ICAM-1 was also studied at the protein level using Western blot 
analysis. IFN-γ increased the protein expression of ICAM-1 (Figure 3.51).  
 
IFN-γ promotes foam cell formation by stimulating the uptake of modified 
lipoproteins (McLaren and Ramji, 2009). Previous study in THP-1 macrophages has 
demonstrated that IFN-γ has propensity to increase foam cell formation (Reiss et al. 
2004). The involvement of IFN-γ in the uptake of modified LDL and foam cell  
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formation was also studied. Results from a single experiment shown in Figure 3.6.2 
showed that IFN-γ induced the AcLDL uptake by macrophages.  
In conclusion, IFN-γ was found to have pro-atherogenic actions on two parameters; 
expression of key genes implicated in inflammation and foam cell formation. 
 
4.3 Action of IL-15 on the expression of MCP-1 and ICAM-1 in macrophages 
IL-15 has been found to promote atherosclerosis in a mouse model of atherosclerosis 
(van Es et al. 2010). Nevertheless, a study in intestinal tissues in Crohn’s disease 
suggested an anti-inflammatory role of IL-15 in this disease (Silva et al. 2005). 
However, its role in macrophages is poorly understood. Van Es et al. (2010) found that 
IL-15 induced the mRNA expression of MCP-1 and had no effect on ICAM-1 in 
RAW264.7 macrophages, suggesting a pro-inflammatory role for IL-15 (van Es et al. 
2010). In contrast with this study, IL-15 was found to inhibit the expression of MCP-1 
mRNA in THP-1 macrophages and have no statistically significant effect on ICAM-1 
mRNA though the trend indicated reduced levels (Figure 3.2.2.2). The latter was also 
suggested when the expression of the ICAM-1 protein was analysed by Western blot 
analysis (Figure 3.5.1). The exact reasons for the differences in the findings between 
THP-1 and RAW264.7 macrophages are at present unclear but could be because of 
species-specific differences. Indeed, species-specific differences are common in 
atherosclerosis, particularly lipoprotein metabolism and the inflammatory response 
(Escola-Gil et al. 2004). For example, mice lack cholesteryl ester transfer protein which 
plays a key role in lipoprotein metabolism in humans by transferring cholesteryl esters 
from HDL to apoB-containing lipoproteins (Tanigawa et al. 2007). In addition, the 
expression of nuclear receptors, such as peroxisome proliferator-activated receptors 
(PPARs) and liver X receptors (LXRs), can be different between mouse and human 
macrophages (Rigamonti et al. 2008). For instance, PPAR-α is abundant in human 
macrophages but barely detectable in mouse macrophages (Rigamonti et al. 2008). 
Furthermore, LXR-α is autoactivated in human but not mouse macrophages (Laffitte et 
al. 2001). 
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To investigate the potential existence of such species-specific differences, some 
experiments were carried out in the mouse macrophage RAW264.7 cell line. Consistent 
with previous studies (van Es et al. 2010), IL-15 enhanced the expression of MCP-1 
mRNA (Figure 3.4.4). ICAM-1 mRNA expression was also found to be increased when 
RAW264.6 cells were stimulated with this cytokine (Figure 3.4.4). Thus, it is likely that 
species-specific actions of IL-15 in atherosclerosis might exist with the cytokine playing 
an anti-atherogenic role in humans and pro-atherogenic role in mice. However, further 
experiments will be required for definitive conclusions. 
 
4.4 Action of IL-20, IL-22 and IL-37 on the expression of MCP-1 and ICAM-1 in 
macrophages 
The production of pro-inflammatory cytokines induced by LPS was found to be totally 
inhibited when  IL-37 was expressed in macrophages, suggesting an anti-inflammatory 
role for this cytokine (Boraschi et al. 2011). On the other hand, IL-20 is expressed in 
atherosclerotic plaques and promotes this disease in apoE deficient mice (Chen et al. 
2006). IL-22 is expressed at high levels in inflamed tissue suggesting a pro-
inflammatory function for this cytokine (Kreymborg and Becher, 2010.). However, the 
roles of these cytokines on the expression of markers of inflammation (i.e. MCP-1 and 
ICAM-1) in human macrophages have not been investigated. The action of IL-37, IL-20 
and IL-22 on the expression of MCP-1 and ICAM-1 was therefore studied but no 
statistically significant results were obtained. The previous anti-inflammatory effect of 
IL-37 was in relation to the action of LPS (Bufler, 2011), which interacts with Toll-like 
receptor 4 (TLR4). The current study was performed with IFN-γ so it is likely that the 
anti-inflammatory action of IL-37 is dependent on the receptor to which the pro-
inflammatory agent interacts with (i.e. TLR4 v/s IFN-γ receptor). The effect of IL-20 in 
particular was surprising given the previously identified pro-atherogenic action in 
mouse model systems (Chen et al. 2006).  However, in this publication, IL-20 was 
found to induce the expression of chemokines Mig/CXXL9 and ITAC/CXCL11 in ECs 
so it is possible that the action of this cytokine might be cell type-specific. 
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4.5 Future work 
 
The studies presented in this thesis involved investigation of the role of more recently 
identified cytokines on macrophage gene expression and uptake of modified LDL in 
relation to atherosclerosis. As only IL-15 affected MCP-1 and ICAM-1 expression, 
further studies focussed on this cytokine. Additional studies on this and other cytokines 
studied are clearly required as part of future work. Some such studies are as follows: 
 
1. The Western blot analysis for ICAM-1 (and MCP-1) was only carried out twice 
so further experiments will be required for statistical analysis; 
2. Complete the experiments on the effect of IFN-γ and IL-15 on the uptake of 
AcLDL using medium containg 0.2% (v/v) fatty acid free BSA; 
3. Confirm findings from cell lines to primary cultures such as human monocyte-
derived macrophages and mouse bonemarrow-derived macrophages to see 
whether species-specific regulation extends to primary cultures; 
4. Analyse the effect of different cytokines on the expression of other genes such 
as scavenger receptors involved in the uptake of modified LDL, genes 
implicated in the efflux of cholesterol (e.g. ABCA-1, apoE). Regulation of M1, 
M2 and other macrophage phenotypes. Other cytokines; and proteases involved 
in the control of plaque stability (McLaren et al. 2011); 
5. In the light of studies on IL-20 that showed an effect on ECs (Chen et al. 2006), 
carry out experiments with all cytokines in other cell types implicated in 
atherosclerosis such as primary aortic ECs and primary vascular SMCs; 
6. Extend the analysis of IL-15, which is restricted to markers of inflammation and 
the uptake of modified LDL, to cholesterol efflux from foam cells (Panousis et 
al. 2001; Michael et al. 2012). In this assay, macrophages are first converted into 
foam cells by incubation with AcLDL in the presence of radiolabelled (tritium) 
cholesterol. The efflux of cholesterol to acceptors, such as HDL or lipid-free 
apoAI, in the absence or presence of IL-15 is then determined by scintillation 
counting of medium and cell lysates. IFN-γ can be used as a control because it 
inhibits cholesterol efflux (Panousis and Zuckerman, 2000; McLaren and Ramji, 
2009);  
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7. Delineate whether the effect of IL-15 on MCP-1 mRNA expression occurs at the 
level of gene transcription or mRNA stability. Control at transcriptional level 
can be determined by nuclear “run-on” transcription assays (Smale, 2009). On 
the other hand, regulation at mRNA stability can be analysed by following the 
decay of MCP-1 and ICAM-1 mRNA, in the absence or the presence of IL-15, 
following inhibition of gene transcription using actinomycin D by RT-qPCR 
(Leclerc et al. 2002). IFN-γ can be used as a control b 
8. ecause it is known to affect the expression of these genes mainly at the level of 
gene transcription (Liu et al. 2004); 
9. If transcription control is involved then delineate cis-acting regulatory sequences 
and trans acting factors involved in the response. The former can be determined 
by transfection assays, in the absence or the presence of the cytokine, using 
promoter-reporter gene constructs that contain deletions or specific mutations in 
the regulatory sequences (Salter et al. 2011) . The interaction of transcription 
factors with such sequences can then be determined by techniques such as 
electrophoretic mobility shift assays (Fried and Crothers, 1981; Harris et al. 
2008) and chromatin immunoprecipitation assays (Thirunavukkarasu et al. 2006; 
Carey et al. 2009); 
10. Delineate signalling pathways using a combination of pharmacological 
inhibitors. Biochemical assays. siRNA-mediated knockdown; and use of 
macrophages from knockout mice (Ali et al. 2010; Michael et al. 2012).    
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Figure 3.2.1.1 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
THP-1 macrophages 
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(B) ICAM-1 
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Figure 3.2.1.2 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
THP-1 macrophages at 24hr 
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(B) ICAM-1 
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IFN-γ3 
21.22 
21.89 
21.7 
21.3 
21.16 
21.52 
18.24 
18.05 
17.79 
18.44 
17.75 
17.78 
2.98 
3.84 
3.91 
2.86 
3.41 
3.74 
3.576667 -0.59667 
0.263333 
0.333333 
-0.71667 
-0.16667 
0.163333 
1.51221856 
0.833160684 
0.793700526 
1.643380629 
1.122462048 
0.892959511  
C1 
C2 
C3 
IFN-γ1 
IFN-γ2 
IFN-γ3 
21.21 
21.48 
22.22 
22.06 
21.81 
21.74 
18.07 
17.55 
17.83 
18.89 
18.07 
18.27 
3.14 
3.93 
4.39 
3.17 
3.74 
3.47 
3.82 -0.68 
0.11 
0.57 
-0.65 
-0.08 
-0.35 
1.602139755 
0.926588062 
0.673616788 
1.569168196 
1.057018041 
1.274560627  
C1 
C2 
C3 
IFN-γ1 
IFN-γ2 
IFN-γ3 
20.35 
20.25 
20.61 
20.09 
20.31 
20.8 
18.07 
17.97 
17.75 
18.91 
18.41 
18.2 
2.28 
2.28 
2.86 
1.18 
1.9 
2.6 
2.473333 -0.19333 
-0.19333 
0.386667 
-1.29333 
-0.57333 
0.126667 
1.143402487 
1.143402487 
0.764894847 
2.450936885 
1.487957514 
0.91594529  
C1 
C2 
C3 
IFN-γ1 
IFN-γ2 
IFN-γ3 
20.76 
20.77 
21.05 
19.27 
19.77 
19.42 
18.76 
17.37 
18.04 
17.75 
17.62 
17.69 
2 
3.4 
3.01 
1.52 
2.15 
1.73 
2.803333 -0.80333 
0.596667 
0.206667 
-1.28333 
-0.65333 
-1.07333 
1.745128575 
0.661280073 
0.866537046 
2.434007027 
1.572797936 
2.104289696  
Sample Relative Expression SD p 
 
Control 1.055505824 0.375916171 
0.035085 IFN-γ 1.543790283 0.543457011 
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Figure 3.2.2.1 IL-15, IL-20 and IL-22 have no effect on MCP-1 and ICAM-1 
mRNA expression in THP-1 macrophages at 3hr 
(A) MCP-1 
Sample MCP-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
24.35 
24.37 
24.14 
25.4 
24.32 
23.91 
24.35 
25.02 
18.62 
18.4 
18.87 
18.04 
18.28 
18.39 
18.33 
18.92 
5.73 
5.97 
5.27 
7.36 
6.04 
5.52 
6.02 
6.1 
5.85 -0.12 
0.12 
-0.58 
1.51 
0.19 
-0.33 
0.17 
0.25 
1.086734863 
0.920187651 
1.494849249 
0.351111219 
0.876605721 
1.257013375 
0.888842681 
0.840896415  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
24.62 
25.27 
24.92 
25.16 
25.16 
25.32 
25.29 
25.01 
17.74 
18.22 
17.71 
18.35 
19.75 
18.61 
19.88 
19.14 
6.88 
7.05 
7.21 
6.81 
5.41 
6.71 
5.41 
5.87 
6.965 -0.085 
0.085 
0.245 
-0.155 
-1.555 
-0.255 
-1.555 
-1.095 
1.060687741 
0.942784536 
0.843815796 
1.113421618 
2.938337267 
1.193335743 
2.938337267 
2.136130816  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
23.38 
23.98 
23.94 
24.29 
24.54 
24.09 
24.2 
24.08 
18.1 
18.05 
17.94 
18.04 
18.06 
17.64 
17.83 
17.89 
5.28 
5.93 
6 
6.25 
6.48 
6.45 
6.37 
6.19 
5.605 -0.325 
0.325 
0.395 
0.645 
0.875 
0.845 
0.765 
0.585 
1.252664439 
0.798298386 
0.760489377 
0.639492791 
0.545253866 
0.556710809 
0.588453369 
0.666649339  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
24.65 
25.09 
23.68 
24.38 
24.23 
16.48 
17.99 
17.36 
17.21 
17.19 
8.17 
7.1 
6.32 
7.17 
7.04 
7.635 
0.535 
-0.535 
-1.315 
-0.465 
-0.595 
0.690158677 
1.448942155 
2.488023307 
1.380317353 
1.510472586  
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IL-20 2 
IL-22 1 
IL-22 2 
24.09 
24.39 
23.68 
16.64 
16.59 
17.32 
7.45 
7.8 
6.36 
-0.185 
0.165 
-1.275 
1.136816973 
0.891928519 
2.419988178 
Sample Relative Expression SD p 
 
Control 1.025057 0.2443359 
0.695029966 
0.457769395 
0.233760736 
IL-15 1.13394 0.6661034 
IL-20 1.251818 0.7607433 
IL-22 1.421403 0.9237739 
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(B) ICAM-1 
 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
21.83 
22.04 
21.96 
21.8 
21.79 
22.12 
22.03 
22.37 
18.62 
18.4 
18.87 
18.04 
18.28 
18.39 
18.33 
18.92 
3.21 
3.64 
3.09 
3.76 
3.51 
3.73 
3.7 
3.45 
3.425 -0.215 
0.215 
-0.335 
0.335 
0.085 
0.305 
0.275 
0.025 
1.160703914 
0.86154616 
1.261377409 
0.792784137 
0.942784536 
0.809442217 
0.826450318 
0.982820599  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
19.55 
20.43 
20.39 
20.46 
22.04 
21.47 
22.34 
21.42 
17.74 
18.22 
17.71 
18.35 
19.75 
18.61 
19.88 
19.14 
1.81 
2.21 
2.68 
2.11 
2.29 
2.86 
2.46 
2.28 
2.01 -0.2 
0.2 
0.67 
0.1 
0.28 
0.85 
0.45 
0.27 
1.148698355 
0.870550563 
0.628506687 
0.933032992 
0.823591017 
0.554784736 
0.732042848 
0.829319546  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
IL-20 2 
IL-22 1 
IL-22 2 
19.91 
20.39 
20.26 
20.6 
20.54 
20.13 
20.58 
20.9 
18.1 
18.05 
17.94 
18.04 
18.06 
17.64 
17.83 
17.89 
1.81 
2.34 
2.32 
2.56 
2.48 
2.49 
2.75 
3.01 
2.075 -0.265 
0.265 
0.245 
0.485 
0.405 
0.415 
0.675 
0.935 
1.20163605 
0.832198735 
0.843815796 
0.71449707 
0.755236293 
0.750019495 
0.626332219 
0.52304247  
C1 
C2 
IL-15 1 
IL-15 2 
IL-20 1 
21.22 
22.43 
21.09 
21.73 
21.04 
16.48 
17.99 
17.36 
17.21 
17.19 
4.74 
4.44 
3.73 
4.52 
3.85 
4.59 
0.15 
-0.15 
-0.86 
-0.07 
-0.74 
0.901250463 
1.109569472 
1.815038311 
1.049716684 
1.670175839  
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IL-20 2 
IL-22 1 
IL-22 2 
21.12 
21.39 
21.51 
16.64 
16.59 
17.32 
4.48 
4.8 
4.19 
-0.11 
0.21 
-0.4 
1.079228237 
0.864537231 
1.319507911 
Sample Relative Expression SD p 
 
Control 1.010769214 0.157437999 0.969719 
IL-15 1.004846136 0.38288849 0.018109 
IL-20 0.723054328 0.304753064 0.120451 
IL-22 0.838006643 0.241709465  
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Figure 3.2.2.2 IL-15 attenuates MCP-1 mRNA expression in THP-1 macrophages 
at 24hr 
(A) MCP-1 
Sample MCP-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
22.38 
23.2 
22.42 
23.05 
23.9 
25.84 
24.36 
24.5 
24.99 
24.27 
25.04 
24.72 
18.24 
18.05 
17.79 
17.76 
18.26 
20.22 
19.99 
18.37 
18.54 
18.23 
18.41 
18.44 
4.14 
5.15 
4.63 
5.29 
5.64 
5.62 
4.37 
6.13 
6.45 
6.04 
6.63 
6.28 
4.64 -0.5 
0.51 
-0.01 
0.65 
1 
0.98 
-0.27 
1.49 
1.81 
1.4 
1.99 
1.64 
1.414213562 
0.702222438 
1.00695555 
0.637280314 
0.5 
0.50697974 
1.205807828 
0.356012549 
0.285190929 
0.378929142 
0.251738888 
0.320856474  
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
24.08 
24.04 
23.99 
23.79 
23.72 
24.02 
24.27 
24.3 
24.63 
24.72 
24.31 
24.07 
18.07 
17.55 
17.83 
17.52 
17.74 
17.41 
17.9 
18.37 
18.06 
18.76 
17.91 
17.97 
6.01 
6.49 
6.16 
6.27 
5.98 
6.61 
6.37 
5.93 
6.57 
5.96 
6.4 
6.1 
6.22 -0.21 
0.27 
-0.06 
0.05 
-0.24 
0.39 
0.15 
-0.29 
0.35 
-0.26 
0.18 
-0.12 
1.156688184 
0.829319546 
1.042465761 
0.965936329 
1.180992661 
0.763129604 
0.901250463 
1.222640278 
0.784584098 
1.197478705 
0.882702996 
1.086734863  
C1 24.7 18.07 6.63 6.813333 -0.18333 1.135504429 
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C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
24.79 
24.74 
25.42 
24.96 
24.65 
24.96 
25.02 
24.82 
24.58 
24.72 
24.74 
17.97 
17.75 
17.76 
17.16 
17.66 
17.59 
18.08 
18.08 
18.7 
18.57 
18.16 
6.82 
6.99 
7.66 
7.8 
6.99 
7.37 
6.94 
6.74 
5.88 
6.15 
6.58  
0.006667 
0.176667 
0.846667 
0.986667 
0.176667 
0.556667 
0.126667 
-0.07333 
-0.93333 
-0.66333 
-0.23333 
0.995389679 
0.884744831 
0.556068043 
0.504642401 
0.884744831 
0.679871186 
0.91594529 
1.052144848 
1.909683208 
1.583737611 
1.175547906 
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
23.66 
24.02 
23.22 
23.99 
24.95 
24.29 
24.51 
25.69 
25.05 
25.24 
25.97 
24.8 
18.76 
17.37 
18.04 
17.2 
17.29 
17.17 
17.13 
18.31 
18.31 
17.8 
17.48 
17.87 
4.9 
6.65 
5.18 
6.79 
7.66 
7.12 
7.38 
7.38 
6.74 
7.44 
8.49 
6.93 
5.576667 -0.67667 
1.073333 
-0.39667 
1.213333 
2.083333 
1.543333 
1.803333 
1.803333 
1.163333 
1.863333 
2.913333 
1.353333 
1.598442299 
0.475219739 
1.316462719 
0.431271016 
0.235968578 
0.343091828 
0.28651184 
0.28651184 
0.446479756 
0.274840528 
0.132739225 
0.391386708  
Sample Relative 
Expression 
SD p 
 
Control 1.046469 0.3097226 
0.005351569 
0.024286578 
0.219406158 
IL-15 0.625842 0.2745566 
IL-20 0.701913 0.3623486 
IL-22 0.798865 0.5900055 
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(B) ICAM-1 
 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
21.22 
21.89 
21.7 
22.63 
22.24 
24.51 
23.33 
22.94 
22.19 
22.05 
22.31 
22.73 
18.24 
18.05 
17.79 
17.76 
18.26 
20.22 
19.99 
18.37 
18.54 
18.23 
18.41 
18.44 
2.98 
3.84 
3.91 
4.87 
3.98 
4.29 
3.34 
4.57 
3.65 
3.82 
3.9 
4.29 
3.576667 -0.59667 
0.263333 
0.333333 
1.293333 
0.403333 
0.713333 
-0.23667 
0.993333 
0.073333 
0.243333 
0.323333 
0.713333 
1.51221856 
0.833160684 
0.793700526 
0.408007242 
0.75610928 
0.60990932 
1.178267139 
0.502315837 
0.950439478 
0.844791174 
0.79922115 
0.60990932  
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
21.21 
21.48 
22.22 
22.3 
21.1 
21.16 
21.92 
22.01 
21.06 
22.7 
21.82 
22.36 
18.07 
17.55 
17.83 
17.52 
17.74 
17.41 
17.9 
18.37 
18.06 
18.76 
17.91 
17.97 
3.14 
3.93 
4.39 
4.78 
3.36 
3.75 
4.02 
3.64 
3 
3.94 
3.91 
4.39 
3.82 -0.68 
0.11 
0.57 
0.96 
-0.46 
-0.07 
0.2 
-0.18 
-0.82 
0.12 
0.09 
0.57 
1.602139755 
0.926588062 
0.673616788 
0.514056913 
1.375541818 
1.049716684 
0.870550563 
1.132883885 
1.765405993 
0.920187651 
0.939522749 
0.673616788  
C1 20.35 18.07 2.28 2.473333 -0.19333 1.143402487 
Hadeel Altuwayjiri                                                                           1008122 
 
 116 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
20.25 
20.61 
21.49 
21.01 
20.66 
20.26 
20.75 
20.63 
20.73 
21.12 
21.11 
17.97 
17.75 
17.76 
17.16 
17.66 
17.59 
18.08 
18.08 
18.7 
18.57 
18.16 
2.28 
2.86 
3.73 
3.85 
3 
2.67 
2.67 
2.55 
2.03 
2.55 
2.95  
-0.19333 
0.386667 
1.256667 
1.376667 
0.526667 
0.196667 
0.196667 
0.076667 
-0.44333 
0.076667 
0.476667 
1.143402487 
0.764894847 
0.418509806 
0.385107556 
0.694156725 
0.872564288 
0.872564288 
0.948246031 
1.359742373 
0.948246031 
0.718636109 
C1 
C2 
C3 
IL-15 1 
IL-15 2 
IL-15 3 
IL-20 1 
IL-20 2 
IL-20 3 
IL-22 1 
IL-22 2 
IL-22 3 
20.76 
20.77 
21.05 
21.27 
20.56 
21.37 
20.74 
21.34 
20.96 
21.17 
20.83 
21.11 
18.76 
17.37 
18.04 
17.2 
17.29 
17.17 
17.13 
18.31 
18.31 
17.8 
17.48 
17.87 
2 
3.4 
3.01 
4.07 
3.27 
4.2 
3.61 
3.03 
2.65 
3.37 
3.35 
3.24 
2.803333 -0.80333 
0.596667 
0.206667 
1.266667 
0.466667 
1.396667 
0.806667 
0.226667 
-0.15333 
0.566667 
0.546667 
0.436667 
1.745128575 
0.661280073 
0.866537046 
0.415618948 
0.723634619 
0.379805666 
0.571701243 
0.854607174 
1.112136086 
0.675174973 
0.684600064 
0.73883972  
Sample Relative Expression SD p    
Control 1.055505824 0.375916171 
0.035085 
0.611121 
0.058666  
IL-15 0.644181215 0.306705746 
IL-20 0.969306834 0.322376588 
IL-22 0.826040675 0.203254389 
 
 
 
 
 
 
Hadeel Altuwayjiri                                                                           1008122 
 
 117 
 
Figure 3.2.3.1 Pre-incubation of THP-1 macrophages with IL-37 for 3hr has no 
effect on MCP-1 and ICAM-1 mRNA expression induced by IFN-γ 
 
(A) MCP-1 
 
Sample MCP-1 Ct GAPDH 
Ct 
ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
27.59 
27.34 
17.87 
17.99 
26.85 
27.01 
18.23 
17.92 
18.61 
18.78 
18.26 
18.67 
18.08 
18.21 
18.54 
18.42 
8.98 
8.56 
-0.39 
-0.68 
8.77 
8.8 
-0.31 
-0.5 
8.77 0.21 
-0.21 
-9.16 
-9.45 
0 
0.03 
-9.08 
-9.27 
0.864537 
1.156688 
572.051 
699.4126 
1 
0.97942 
541.1932 
617.3736  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
22.22 
22.54 
17.32 
18.23 
22.98 
22.48 
16.75 
17.33 
18.8 
18.7 
18 
20.91 
17.68 
18.17 
18.19 
17.65 
3.42 
3.84 
-0.68 
-2.68 
5.3 
4.31 
-1.44 
-0.32 
3.63 -0.21 
0.21 
-4.31 
-6.31 
1.67 
0.68 
-5.07 
-3.95 
1.156688 
0.864537 
19.83532 
79.34129 
0.314253 
0.624165 
33.59093 
15.45498  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
22.39 
23.11 
17.68 
17.1 
22.26 
22.47 
16.66 
17.14 
17.98 
17.78 
17.5 
17.82 
17.25 
17.33 
17.3 
18.2 
4.41 
5.33 
0.18 
-0.72 
5.01 
5.14 
-0.64 
-1.06 
4.87 -0.46 
0.46 
-4.69 
-5.59 
0.14 
0.27 
-5.51 
-5.93 
1.375542 
0.726986 
25.81254 
48.1679 
0.907519 
0.82932 
45.56961 
60.96883  
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Sample Relative 
Expression 
SD p  
Control 1.024163 0.244077 0.116054 
0.159048 
0.115305 
0.279957 
IFN-γ 240.7701 309.281 
IL-37 0.77578 0.263803 
IL-37+ IFN-γ 219.0252 280.4885 
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(B) ICAM-1 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
22.55 
22.69 
19.93 
20.11 
22.46 
22.62 
19.61 
18.89 
18.61 
18.78 
18.26 
18.67 
18.08 
18.21 
18.54 
18.42 
3.94 
3.91 
1.67 
1.44 
4.38 
4.41 
1.07 
0.47 
3.925 0.015 
-0.015 
-2.255 
-2.485 
0.455 
0.485 
-2.855 
-3.455 
0.989656656 
1.010451446 
4.773342972 
5.598343462 
0.729510172 
0.71449707 
7.23503502 
10.96626244  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
20.23 
20.21 
18.93 
20.84 
20.29 
20.06 
18.6 
18.36 
18.8 
18.7 
18 
20.91 
17.68 
18.17 
18.19 
17.65 
1.43 
1.51 
0.93 
-0.07 
2.61 
1.89 
0.41 
0.71 
1.47 -0.04 
0.04 
-0.54 
-1.54 
1.14 
0.42 
-1.06 
-0.76 
1.028113827 
0.972654947 
1.453972517 
2.907945035 
0.453759578 
0.747424624 
2.084931522 
1.693490625  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
20.64 
21.21 
20.03 
19.55 
20.52 
20.68 
18.53 
18.67 
17.98 
17.78 
17.5 
17.82 
17.25 
17.33 
17.3 
18.2 
2.66 
3.43 
2.53 
1.73 
3.27 
3.35 
1.23 
0.47 
3.045 -0.385 
0.385 
-0.515 
-1.315 
0.225 
0.305 
-1.815 
-2.575 
1.305859787 
0.765778999 
1.42899414 
2.488023307 
0.855595026 
0.809442217 
3.518596304 
5.958709852  
Sample Relative 
Expression 
SD p 
 
Control 1.012086 0.172793 0.034624 
0.019098 
0.034128 
0.069734 
IFN-γ 3.108437 1.83157 
IL-37 0.718371 0.140091 
IL-37+ IFN-γ 5.242838 3.543506 
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Figure 3.2.3.2 Pre-incubation of THP-1 macrophages with IL-37 for 24hr has no 
effect on MCP-1 and ICAM-1 mRNA expression induced by IFN-γ 
 
(A) MCP-1 
 
Sample MCP-1 Ct GAPDH 
Ct 
ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
26.31 
27.53 
18.8 
18.06 
27.04 
26.78 
17.79 
17.74 
18.36 
18.46 
19.27 
18.62 
20.26 
18.25 
18.2 
18.9 
7.95 
9.07 
-0.47 
-0.56 
6.78 
8.53 
-0.41 
-1.16 
8.51 
-0.56 
0.56 
-8.98 
-9.07 
-1.73 
0.02 
-8.92 
-9.67 
1.474269 
0.678302 
504.9511 
537.4549 
3.317278 
0.986233 
484.3815 
814.6294  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
23.51 
23.13 
19.24 
19.31 
24.05 
24.34 
19.11 
18.7 
17.98 
17.19 
17.19 
17.6 
17.52 
17.57 
17.97 
17.82 
5.53 
5.94 
2.05 
1.71 
6.53 
6.77 
1.14 
0.88 
5.735 
-0.205 
0.205 
-3.685 
-4.025 
0.795 
1.035 
-4.595 
-4.855 
1.152686 
0.867539 
12.86162 
16.27968 
0.576343 
0.488016 
24.16756 
28.94014  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
22.33 
23.03 
18.03 
18.55 
22.83 
22.95 
18.02 
18.46 
18.55 
20.11 
18.31 
18.57 
4.31 
4.57 
-0.52 
-1.56 
4.52 
4.38 
4.44 
-0.13 
0.13 
-4.96 
-6 
0.08 
-0.06 
1.094294 
0.913831 
31.12496 
64 
0.946058 
1.042466  
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IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
17.77 
17.96 
18.09 
18.35 
-0.32 
-0.39 
-4.76 
-4.83 
27.09585 
28.44297 
Sample Relative 
Expression 
SD p 
 
Control 0.913831 0.275732 0.121081 
0.604575 
0.151252 
0.440934 
IFN-γ 194.4454 253.9585 
IL-37 1.226066 1.049729 
IL-37+ IFN-γ 234.6096 337.9235 
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(B) ICAM-1 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
21.06 
21.34 
20.13 
19.67 
22.79 
21.71 
19.06 
19.25 
18.36 
18.46 
19.27 
18.62 
20.26 
18.25 
18.2 
18.9 
2.7 
2.88 
0.86 
1.05 
2.53 
3.46 
0.86 
0.35 
2.79 -0.09 
0.09 
-1.93 
-1.74 
-0.26 
0.67 
-1.93 
-2.44 
1.064370182 
0.939522749 
3.810551992 
3.340351678 
1.197478705 
0.628506687 
3.810551992 
5.42641731  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
19.84 
19.61 
17.58 
18.22 
19.53 
19.7 
18.45 
17.95 
17.98 
17.19 
17.19 
17.6 
17.52 
17.57 
17.97 
17.82 
1.86 
2.42 
0.39 
0.62 
2.01 
2.13 
0.48 
0.13 
2.14 -0.28 
0.28 
-1.75 
-1.52 
-0.13 
-0.01 
-1.66 
-2.01 
0.823591017 
1.214194884 
0.297301779 
0.348685917 
0.91383145 
0.993092495 
0.316439148 
0.248273124  
C1 
C2 
IFN-γ1 
IFN-γ2 
IL-37 1 
IL-37 2 
IL-37+ IFN-γ1 
IL-37+I IFN-γ2 
20.04 
20.41 
18.67 
19.95 
20.65 
20.74 
18.42 
18.42 
18.02 
18.46 
18.55 
20.11 
18.31 
18.57 
18.09 
18.35 
2.02 
1.95 
0.12 
-0.16 
2.34 
2.17 
0.33 
0.07 
1.985 0.035 
-0.035 
-1.865 
-2.145 
0.355 
0.185 
-1.655 
-1.915 
0.976031761 
1.024556823 
3.642679334 
4.422922613 
0.781869643 
0.879649076 
3.149231906 
3.771138144  
Sample Relative 
Expression 
SD p 
   
Control 1.007045 0.130905 0.081169 
0.199601 
0.199601 
0.737628  
IFN-γ 2.643749 1.83211 
IL-37 0.899071 0.192574 
IL-37+ IFN-γ 2.787009 2.081477 
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Figure 3.4.3 IFN-γ induces the expression of MCP-1 and ICAM-1 mRNA in 
RAW264.7 macrophages 
(A) MCP-1 
Sample MCP-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
19.78 
18.77 
17.32 
17.05 
15.83 
15.82 
15.22 
15.33 
3.95 
2.95 
2.1 
1.72 
3.45 0.5 
-0.5 
-1.35 
-1.73 
0.707107 
1.414214 
2.549121 
3.317278  
C1 
C2 
IFN-γ1 
IFN-γ2 
22.81 
22.26 
22.12 
20.53 
14.35 
14.09 
14.85 
14.77 
8.46 
8.17 
7.27 
5.76 
8.315 0.145 
-0.145 
-1.045 
-2.555 
0.904379 
1.105731 
2.063366 
5.876675  
C1 
C2 
IFN-γ1 
IFN-γ2 
21.35 
20.83 
19.3 
20.25 
15.31 
15.57 
15.83 
16.25 
6.04 
5.26 
3.47 
4 
5.65 0.39 
-0.39 
-2.18 
-1.65 
0.76313 
1.310393 
4.531536 
3.138336  
Sample Relative 
Expression 
SD p 
 
Control 1.034158897 0.290906258 
0.006673 IFN-γ 3.579385377 1.400507738 
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(B) ICAM-1 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C2 
IFN-γ1 
IFN-γ2 
23.29 
23.44 
21.51 
21.36 
15.83 
15.21 
15.22 
15.33 
7.46 
8.23 
6.29 
6.03 
7.845 -0.385 
0.385 
-1.555 
-1.815 
1.305859787 
0.765778999 
2.938337267 
3.518596304  
C1 
C2 
IFN-γ1 
IFN-γ2 
23.13 
22.11 
20.05 
19.85 
16.03 
16.01 
15.75 
14.68 
7.1 
6.1 
4.3 
5.17 
6.6 0.5 
-0.5 
-2.3 
-1.43 
0.707106781 
1.414213562 
4.924577653 
2.694467154  
C1 
C2 
IFN-γ1 
IFN-γ2 
21.38 
21.52 
20.44 
19.73 
15.31 
15.57 
15.83 
16.25 
6.07 
5.95 
4.61 
3.48 
6.01 0.06 
-0.06 
-1.4 
-2.53 
0.959264119 
1.042465761 
2.639015822 
5.775716782  
Sample Relative 
Expression 
SD p 
 
Control 1.032448168 0.283871256 
0.006047 IFN-γ 3.74845183 1.30720513 
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Figure 3.4.4 IL-15 induces the expression of MCP-1 and ICAM-1 mRNA in 
RAW264.7 macrophages 
(A) MCP-1 
Sample MCP-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C 2 
IL-15 1 
IL-15 2 
21.54 
21.58 
21.61 
20.93 
14.04 
15.69 
16.16 
16.37 
7.5 
5.89 
5.45 
4.56 
6.695 
0.805 
-0.805 
-1.245 
-2.135 
0.572362 
1.747146 
2.370186 
4.392371  
C1 
C 2 
IL-15 1 
IL-15 2 
22.71 
21.11 
20.71 
21.11 
16.78 
15.42 
16.06 
16.32 
5.93 
5.69 
4.65 
4.79 
5.81 
0.12 
-0.12 
-1.16 
-1.02 
0.920188 
1.086735 
2.234574 
2.027919  
C1 
C 2 
IL-15 1 
IL-15 2 
20.84 
21.9 
20.35 
20.62 
17.17 
17.4 
17.51 
17.88 
3.67 
4.5 
2.84 
2.74 
4.085 
-0.415 
0.415 
-1.245 
-1.345 
1.333299 
0.750019 
2.370186 
2.540302  
Sample Relative 
Expression 
SD p 
 
control 1.068291426 0.424403091 
0.001653 IL-15 2.655922923 0.86762162 
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(B) ICAM-1 
Sample ICAM-1 Ct GAPDH Ct ΔCt Average 
control 
ΔCt  
ΔΔCt 2- ΔΔCt 
C1 
C 2 
IL-15 1 
IL-15 2 
21.96 
23.96 
23.21 
22.4 
14.04 
15.69 
16.16 
15.82 
7.92 
8.27 
7.05 
6.58 
8.095 -0.175 
0.175 
-1.045 
-1.515 
1.128964405 
0.885767519 
2.063366359 
2.857988279  
C1 
C 2 
IL-15 1 
IL-15 2 
22.6 
22.34 
20.09 
20.71 
15.24 
15.28 
15.46 
16.75 
7.36 
7.06 
4.63 
3.96 
7.21 0.15 
-0.15 
-2.58 
-3.25 
0.901250463 
1.109569472 
5.979396995 
9.51365692  
C1 
C 2 
IL-15 1 
IL-15 2 
20.26 
22.64 
20.45 
19.7 
15.24 
16.78 
15.46 
16.75 
5.02 
5.86 
4.99 
2.95 
5.44 -0.42 
0.42 
-0.45 
-2.49 
1.337927555 
0.747424624 
1.366040257 
5.617779503  
Sample Relative 
Expression 
SD p 
 
control 1.018484006 0.213249722 
0.039575 IL-15 4.566371385 3.066054823 
 
